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RESUMEN 
INTRODUCCIÓN 
Los linfocitos CD4 naíf se diferencian a distintos subtipos de células efectoras Th (Th1, Th2, 
Th17 y Treg) tras ser estimulados por células presentadoras de antígeno (APCs) en el ganglio 
linfático. Las células Th generadas migran a la periferia, donde un segundo encuentro con el 
mismo antígeno presentado por APCs conducirá a su activación y función efectora. Tanto la 
activación inicial de la célula naíf en el ganglio como la reactivación de la célula efectora en la 
periferia tienen lugar en el contexto de la sinapsis inmunológica (IS), un contacto dinámico y 
especializado entre una APC y un linfocito. El contacto inicial entre el linfocito T y la APC ocurre 
en el lamelipodio, donde la estimulación del receptor de la célula T (TCR) y la señalización a 
través de moléculas de adhesión y de coestimulación induce reordenamientos en el 
citoesqueleto que estabilizan el contacto, conduciendo a la formación de una IS madura. La 
estimulación por TCR y moléculas coestimuladoras desencadena redes de señalización que 
conducen a la activación del linfocito T y su función efectora. La dinámica de actina juega un 
papel fundamental tanto en el establecimiento de la IS como en la progresión de la 
señalización necesaria para alcanzar la completa activación del linfocito T. Las redes de 
señalización inducidas durante la estimulación y diferenciación de la célula T están controladas 
por fosfo/defosforilación tanto de proteínas como de fosfoinosítidos. Miembros de la familia 
de las proteínas fosfatasas de tyrosina (PTPs) defosforilan estos sustratos. Más de la mitad de 
las PTPs pueden también defosforilar residuos de serina y treonina, y pueden definirse como 
PTPs no clásicas (NC). El papel de un gran número de PTPs NC en la regulación de la 
diferenciación Th, en el ensamblaje de la IS y en la activación de la célula T son desconocidos. 
HIPÓTESIS Y OBJETIVOS 
Dado que los linfocitos T expresan un gran número de PTPs, que son importantes reguladores 
de los niveles de fosforilación en la célula, nuestra hipótesis fue que algunas PTPs NC son 
reguladores de la activación y diferenciación T. Para verificar esta hipótesis, decidimos (i) 
estudiar cambios en el perfil de expresión de PTPs NC durante la polarización y reestimulación 
Th1 y (ii) estudiar el reclutamiento a la IS y el papel regulador en el ensamblaje de la IS y en la 
señalización por el TCR de la PTP NC PRL-1. 
RESULTADOS Y DISCUSIÓN 
El estudio del perfil de expresión de PTPs durante la polarización y reestimulación Th1 reveló 
cambios en los niveles de expresión de varias PTPs, algunas de las cuales tienen una función 
desconocida en la activación y diferenciación T. Entre las PTPs reguladas durante la 
reestimulación Th1, la familia de las fosfatasas de regeneración hepática (PRLs) mostró 
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diferente regulación de cada uno de sus tres miembros: la expresión de PTP4A1 (que codifica 
para PRL-1) y de PTP4A2 (que codifica para PRL-2) incrementó y disminuyó, respectivamente, 
mientras que la de PTP4A3 (que codifica para PRL-3) no cambió. Además, el tratamiento con 
un inhibidor de la actividad catalítica de las PRLs redujo la expresión de CD69 y la secreción de 
IL-2, sugiriendo que las PRLs participan en la activación T. El aumento de expresión de PTP4A1 
durante la estimulación T y su papel como regulador del citoesqueleto de actina descrito en la 
literatura nos condujo a estudiar su reclutamiento a la IS. PRL-1 se reclutaba inicialmente a las 
membranas que escanean la APC, y posteriormente se polarizaba a la IS junto con el 
compartimento endosomal. Además, PRL-1 colocalizaba con LFA-I y CD3 en la sinapsis madura. 
Experimentos de microscopía de reflexion interna total confirmaron copresencia de PRL-1 y 
CD3ζ en la IS y durante el contacto inicial con superficies activadoras. En conjunto, estos datos 
sugieren que PRL-1 participa en la dinámica y señalización del TCR en la IS. El reclutamiento 
inicial de PRL-1 a las membranas que escanean la APC nos llevó a estudiar el papel de esta 
proteína en la dinámica de actina durante el ensamblaje de la IS. La sobreexpresión de PRL-1 
provocó un defecto en el aclaramiento de actina y en la extensión de la célula T sobre 
superficies activadoras, mientras que la inhibición de la actividad catalítica provocó una 
disminución en la polimerización de actina en la IS. Estos efectos sobre el citoesqueleto de 
actina podrían deberse a la regulación de las Rho GTPasas Rac1, Cdc42 y RhoA por PRL-1. Por 
último, la sobreexpresión de PRL-1 condujo a mayores niveles de inducción de CD69, de 
secreción de IL-2 y de activación de fosfolipasa C γ 1 (PLCγ1), mientras que la inhibición de la 
actividad catalítica de PRL-1 tuvo el efecto opuesto. La activación de PLCγ1 requiere una 
adecuada polimerización de actina en la IS. Por tanto, en nuestro sistema, la disminución en la 
polimerización de actina cuando PRL-1 es inhibido podría causar una deficiente activación de 
PLCγ1, disminuyendo la secreción de IL-2. Por el contrario, el aumento en la polimerización de 
actina en el área de contacto inducido por la sobreexpresión de PRL-1 resultaría en una mayor 
activación de PLCγ1, conduciendo a mayor secreción de IL-2. 
CONCLUSIONES 
En este trabajo, hemos descrito que el perfil de expresión de PTPs NC se modifica de manera 
significativa durante la polarización Th1, sugiriendo que las células naíf y las células efectoras 
requieren distintos niveles de estas enzimas. Además, mostramos que la expresión de diversas 
NC PTPs se regula durante la estimulación Th1, lo que sugiere que algunas de estas enzimas 
podrían ser nuevos reguladores de las respuestas T. Respecto a la regulación de las PRLs, 
encontramos que durante la estimulación T la expresión de PTP4A1 y PTP4A2 se equilibra. Los 
estudios realizados en PRL-1 mostraron que ésta se recluta a la IS, donde regula los 
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reordenamientos de actina y donde regula positivamente la activación de PLCγ1 y la secreción 
de IL-2. En conjunto, nuestros datos alientan futuras investigaciones sobre el papel de PTPs NC 
en las respuestas T y proporcionan evidencias de que PRL-1 es un regulador positivo de la 
estimulación T.  
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SUMMARY 
INTRODUCTION 
Stimulation of naïve CD4 T cells in the lymph node by antigen presenting cells (APCs) induces 
their differentiation into effector T helper (Th) cells. Effector Th cells then migrate to 
peripheral sites, where a secondary encounter with the same antigen presented by APCs will 
lead to their activation and effector function, including secretion of appropriate cytokines. 
Both the initial activation of naïve cells in the lymph node and the reactivation of effector cells 
in the periphery take place in the context of the immunological synapse (IS). The IS is a 
specialized dynamic contact between an APC and a lymphocyte. Initial contact between a 
migrating T cell and an APC takes place at the leading lamellipodium, where T cell receptor 
(TCR) engagement and signaling through adhesion and costimulatory molecules induces 
cytoskeletal rearrangements that stabilize the contact, leading to the formation of a mature IS. 
Recognition of the antigen by the TCR, together with costimulation, triggers the activation of 
signaling networks that lead to full T cell activation and effector function. Actin dynamics play 
a central role in both the establishment of the IS and the progression of sustained signaling 
required for full T cell activation. One of the subsets in which naïve CD4 T cells can 
differentiate is the Th1. This subset produces interferon γ (IFNγ) and is specific for intracellular 
pathogens. Polarization to the Th1 phenotype is promoted by IL-12 and IFNγ, and is initiated 
during stimulation at the IS. The signaling networks induced during T cell stimulation and 
differentiation are controlled by phospho/dephosphorylation of both proteins and 
phosphoinositides. Protein tyrosine phosphatases (PTPs) dephosphorylate a wide range of 
substrates. This family is formed of more than a hundred genes, among which more than a half 
are also able to dephosphorylate serine or threonine residues, and can be defined as non 
classical (NC) PTPs. Interestingly, the role of a high number of NC PTPs in the regulation of Th 
differentiation, IS assembly and T cell activation remains unknown. 
HYPOTHESIS AND OBJECTIVES 
Given that T cells express a high number of PTPs, which are key regulators of phosphorylation 
levels in the cell, we hypothesized that some NC PTPs are yet unknown regulators of T cell 
activation and differentiation. To verify this hypothesis, we decided (i) to study the changes in 
the expression profile of NC PTPs during Th1 polarization and restimulation and (ii) to study 
the recruitment to the IS and the regulatory role in IS assembly and signaling downstream the 
TCR exerted by the NC PTP PRL-1.  
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RESULTS AND DISCUSSION 
Study of the expression profile of PTPs during Th1 polarization and restimulation revealed 
changes in the expression levels of several PTPs, some of them with unknown function in T cell 
activation and differentiation. Among the PTPs regulated during Th1 restimulation, the family 
of phosphatases of regenerating liver (PRLs) showed differential regulation of each of its three 
genes: the expression of PTP4A1 (coding for PRL-1) and PTP4A2 (coding for PRL-2) were up- 
and downregulated, respectively, while PTP4A3 (coding for PRL-3) did not change. Besides, 
treatment of CD4 T cells with an inhibitor of PRL catalytic activity resulted in reduced CD69 
expression and IL-2 secretion, suggesting that PRLs participate in T cell activation. The 
upregulation of PTP4A1 during T cell stimulation and its role as regulator of the actin 
cytoskeleton reported in the literature prompted us to study its delivery to the IS. We found an 
initial delivery of PRL-1 to scanning membranes of T cells, and a later delivery to the stablished 
IS with the endosomal compartment. Besides, PRL-1 colocalized with LFA-I and CD3 at the 
mature IS. Total internal reflection microscopy experiments further confirmed copresence of 
PRL-1 and CD3ζ at the stablished IS and during initial contact with activating surfaces. 
Altogether, these data suggest that PRL-1 participates in TCR dynamics and signaling 
downstream the TCR and LFA-I at the IS. Consistent with this idea, we found that PRL-1 
overexpression leads to increased CD69 induction and IL-2 secretion, while inhibition of PRL-1 
catalytic activity had the opposite effect, indicating that PRL-1 regulates T cell activation.  
Initial delivery of PRL-1 to scanning membranes prompted us to study the role of this protein 
in actin dynamics during IS assembly. Overexpression of PRL-1 resulted in defective actin 
clearance and impaired cell spreading, while inhibition of PRL-1 catalytic activity resulted in 
decreased actin polymerization at the IS. These effects on actin dynamics could be due to 
regulation of the Rho family GTPases Rac1, Cdcd42 and RhoA by PRL-1. Proper actin 
polymerization at the IS is critical for phospholipase C γ 1 activation. Interestingly, we found 
that PRL-1 overexpression leads to increased PLCγ1 activation, while PRL-1 inhibiton has the 
opposite effect. Hence, in our system, decreased actin polymerization when PRL-1 is inhibited 
could cause defective PLCγ1 activation, leading to deficient IL-2 secretion. By contrast, 
increased actin polymerization at the area of contact induced by PRL-1 overexpression would 
result in enhanced PLCγ1 activation, leading to increased IL-2 secretion.  
CONCLUSIONS 
In this work, we found that the expression profile of NC PTPs is significantly modified during 
Th1 polarization, suggesting a different requirement of these enzimes in naïve versus effector 
cells. Besides, we showed that the expression of several NC PTPs is regulated during Th1 
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stimulation, suggesting that some of these enzimes could be novel regulators of T cell 
responses.  Regarding regulation of PRL phosphatases, we found that after activation, PTP4A1 
and PTP4A2 have a more balanced expression than before activation. Focusing on PRL-1, we 
found that it is recruited to the IS, where it regulates actin rearrangements during IS assembly 
and where it positively regulates PLCγ-1 activation and IL-2 secretion. Altogether, our data 
encourage further research on the role of NC PTPs in T cell responses and provide evidences 
that PRL-1 is a positive regulator of T cell stimulation. 
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ABBREVIATIONS 
 
Table A1. List of abbreviations 
Abbreviation Full name 
A3 Analog 3 
AP-1 Activator protein-1 
APC Antigen presenting cell 
ARP 2/3 Actin-related protein 2/3 
Asp Aspartic acid 
ATF Activating transcription factor 
bp Base pairs 
CDC14(s) Cell division cycle-14 protein(s) 
CDC25(s) Cell division cycle-25 protein(s) 
CDK(s) Cyclin-dependent kinase(s)  
CMAC 7-amino-4-chloromethyl coumarin 
CRISPR Clustered regularly interspaced short palindromic repeats 
cSMAC  Central SMAC 
Cys Cysteine 
DAG Diacylglycerol 
DC Dendritic cell 
DCT Delta CT 
DNA Deoxyribonucleic acid 
DSB Double strand break 
dSMAC Distal SMAC 
DSP(s) Dual specific phosphatase(s) 
ELISA Enzyme-Linked Immunosorbent Assay 
ERK1/2 Extracellular signal activated kinase1/2 
Eya(s) Eyes absent phosphatase(s) 
F-actin Filamentous actin 
FAK Focal-adhesion kinase 
FCS Fetal calf serum 
Foxp3 Forkhead box P3 
GADS Grb2-Related Adaptor Downstream of Shc 
GATA3 GATA-binding protein 3 
GEF Guanine nucleotide exchange factor 
GFP Green fluorescent protein 
Grb2 Growth factor receptor-bound protein 2 
HA Homology arm 
HS1 Hematopoietic lineage cell-specific protein 1 
ICAM-1 Intercellular adhesion molecule 1 
IFNγ Interferon γ 
IFNγ-R IFNγ receptor 
IP Immunoprecipitation 
IP3 Inositol 1,4,5-triphosphate  
IS Immunological synapse 
ITAM(s) Immunotyrosine-based activation motif(s) 
Itk Interleukin-2-inducible tyrosine kinase 
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Table A1. List of abbreviations (continuation) 
Abbreviation Full name 
JNK c-Jun N-terminal kinase 
KDa Kilodalton 
LAT Linker for activation of T cells 
Lck Leukocyte C-terminal Src kinase 
LFA-I Lymphocyte function-associated antigen 1 
LIMK LIM kinase 
LMPTP Low-molecular-weight PTP 
MAPK Mitogen-activated protein kinase 
MHC-II Major histocompatibility complex 
MKP(s) MAPK phosphatase(s) 
mRNA Messenger ribonucleic acid 
MTM(s) Myotubularin(s) 
MTOC Microtubule organizing center 
NC Non classical 
Nck Non-catalytic region of tyrosine kinase 
NF-κB Nuclear factor κ B 
NFAT Nuclear factor of activated T cells 
NRPTPs Non receptor PTPs 
PAM Protospacer adjacent motif 
PBS Phosphate-buffered saline 
PB3 Procyanidin B3 
PD Phosphatase dead 
PMA phorbol 12-myristate 13-acetate 
PIP2 Phosphatidylinositol (4,5)-biphosphate 
PIP3 phosphatidylinositol (3,4,5)-triphosphate 
PI(3,5)P2 phosphatidylinositol (3,5)-biphosphate 
PI3K Phosphatidylinositol 3 kinase 
PI3P Phosphatidylinositol 3-phosphate 
PKC-θ Protein kinase C θ 
PLCγ1 Phospholipase C γ 1 
PRL(s) Protein(s) of regenerating liver 
pSMAC Peripheral SMAC 
PTEN(s) Phosphatase and tensin homolog(s) 
PTP(s) Protein tyrosine phosphatase(s) 
ROCK Rho-associated protein kinase 
RORγt RAR-related orphan receptor γt 
RPTPs Receptor type PTPs 
SEE Staphylococcal enterotoxin E  
Ser Serine 
Sg Single guide 
SLP76 SH2 domain-containing leukocyte protein of 76 kDa 
SMAC Supramolecular activation cluster 
STAT Signal transducer and activator of transcription 
SSH(s) Slingshot(s) 
TCR T cell receptor 
TGF-β Transforming growth factor β 
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Table A1. List of abbreviations (continuation) 
Abbreviation Full name 
Th T helper 
Thr Threonine 
TIRFM Total internal reflection fluorescence microscopy 
TP Thienopyridone 
Treg T regulatory 
Tyr Tyrosine 
VHR Vaccinia H1-related protein 
WASp Wiskott Aldrich syndrome protein 
WB Western Blot 
ZAP70 ζ-chain associated protein kinase 70 
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INTRODUCTION 
 
1. CD4 T cells 
 
The immune system is formed of two types of immunity: the innate and the adaptive. The 
innate immunity is important in the initial containment of the infection, and generates an 
environment where cells of the adaptive immunity activate, proliferate, and differentiate into 
cells with effector functions appropriate for an efficient response. CD4 or helper T cells (Th) 
are fundamental players of adaptive immunity, due to the heterogeneity of their effector 
functions and their capacity to induce memory (1). They are characterized by the expression of 
the costimulatory molecule CD4 and the capacity to recognize antigens presented in the 
context of the class II major histocompatibility complex (MHC-II) by antigen presenting cells 
(APCs). In addition to their pivotal role in the defence against pathogens, Th cells have been 
shown to be essential players in autoimmune and inflammatory diseases (2). Therefore, 
understanding the mechanisms that regulate CD4 T cell responses could open new possibilities 
for therapy of both infectious and autoimmune diseases. 
 
Generation of differentiated effector Th cells involves several processes in different 
compartments of the body (Figure I1). T cell precursors migrate from the bone marrow to the 
thymus, where they undergo a maturation process that includes positive and negative 
selection (3). Mature CD4 T cells leave the thymus as naïve T cells, characterized by the 
expression of the RA splicing variant of the CD45 phosphatase (CD45RA) (4). Naïve CD4 T cells 
circulate in the bloodstream until they reach the lymph nodes, where they scan dendritic cells 
(DCs) for specific peptides presented in the MHC-II (5). After a first phase of serial contacts, 
naïve T cells establish long-lasting contacts with DCs, in which antigen presentation by the APC 
results in T cell activation, proliferation and differentiation into effector T cells (6). Antigen-
experienced cells loose expression of CD45RA and express CD45RO, a shorter form of CD45 (4). 
The encounter with the antigen presented by DCs also determines the differentiation of CD4 T 
cells into one of at least four subsets of effector Th cells: Th1, Th2, Th17 and Treg (7). 
Generated effector Th cells can either remain within the lymph node to help B cells or leave 
the organ through the efferent lymphatic vessels to reach sites of infection. Once in the 
infected tissue, Th cells exert their effector functions upon additional activation by APCs. All 
the initial activation of naïve T cells in the lymph node by DCs, the cooperation with B cells and 
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the secondary activation in infected tissues involve the formation of a specialized contact 
between the T cell and the APC, called the immunological synapse (IS) (8).  
 
 
 
Figure I1.  Generation of effector CD4 T cells. The main compartments of the body where take place the initial T cell 
maturation, antigen encounter, generation of effector Th cells, cooperation with B cells and effector function at the 
periphery are schematized.  
 
 
2. The IS 
 
As mentioned before, in vivo T cell activation involves the formation of the IS, an organized, 
dynamic contact between a lymphocyte and an APC. This structure allows for bidirectional 
exchange of information between cells, although in this work we will focus on the T cell side of 
the IS. Signaling downstream the T cell receptor (TCR), costimulatory molecules and integrins 
takes place in the context of the IS and leads to full T cell activation, differentiation, and 
effector function. 
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2.1 Formation and structure of the IS 
The formation of the IS starts when a T cell that expresses a TCR for a specific peptide-MCH (p-
MCH) complex interacts with an APC presenting the same p-MCH complex. The initial contact 
takes place at the leading lamellipodium, where p-MHC recognition by the TCR enhances LFA-I 
(lymphocyte function-associated antigen 1)-mediated adhesion, generating an adhesive 
surface that, together with the action of the actin cytoskeleton, stops T cell migration and 
induces the formation of an increasingly stable cell contact with the APC (Figure I2) (9). 
 
LFA-I-mediated adhesion, costimulation by CD28, and TCR signaling trigger actin 
polymerization at the lamellipodium, which leads to cell spreading over the APC (10). Activated 
TCRs, CD28, adaptors such as SH2 domain-containing leukocyte protein of 76 KDa (SLP-76) and 
kinases such as protein kinase C θ (PKC-θ) or ζ-chain associated protein kinase 70 (ZAP70) form 
microclusters at the periphery of the IS, where signaling starts (11) (Figure I2).  At the 
periphery of the interaction, addition of actin monomers to branched actin filaments and actin 
severing by depolymerizing factors generates a centripetal retrograde flow of actin that, 
together with contraction of acto-myosin arcs, drives movement of microclusters to the centre 
of the interaction (12), where signal extinction takes place (11, 13, 14) (Figure I2). The actin 
flow is critical for sustaining signaling to achieve T cell activation (15). Besides, the microtubule 
organizaing center (MTOC) is translocated to the IS within minutes after cell contact, together 
with the surrounding endosomal compartment (16, 17) (Figure I2). Positioning of the MTOC 
and microtubule dynamics has been shown to be critical for sustaining TCR signaling, supplying 
molecules from intracellular pools and maintaining IS architecture (18, 19). In addition, 
microtubules underlying the IS provide the tracks for movement of signaling microclusters to 
the center of the interaction in a mechanism that requires dynein (20).  
 
While microclusters migrate, the bull's eye pattern first described by Kupfer and co-workers 
(21) is formed. This pattern consists of three concentrical structures called SMACs 
(supramolecular activation clusters) (Figure I2). The central SMAC (cSMAC) is enriched in TCR, 
costimulatory molecules such as CD28, and intracellular signalling molecules such as protein 
kinase C θ (PKC-θ) (21). Further analysis of the cSMAC has reveleaded that this area can be 
further subdivided in a central CD3high region, where TCR and CD3 accumulate prior to 
internalization and degradation (14, 22), and a surrounding CD3low region enriched in other 
signaling molecules (Figure I2) (23, 24).  A peripheral ring named peripheral SMAC (pSMAC) 
with high density of LFA-1 and its associated protein talin surrounds the cSMAC (21). Finally, 
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the more distal zone of the interaction is called distal SMAC (dSMAC), and contains molecules 
that are excluded from the IS due to its large size, such as CD43 (25).  Regarding the actin 
cytoskeleton, the dSMAC is enriched in a branched filamentous actin (F-actin) network that 
gives way to a zone of actomyosin arcs at the pSMAC, while the cSMAC is depleted of F-actin 
(26) (Figure I2).  
 
 
Figure I2. Formation and structure of the IS.  In the upper side, a migrating T cell establishing contact with an APC 
through the leading lamellipodium is shown (left). TCR signaling and actin rearrangements lead to the formation of 
a mature IS (right). In the lower part, a frontal view of the T cell side of the mature IS as described by Saito and co-
workers using planar bilayers (23, 24) is depicted. Filamentous actin is indicated as a yellow network. Actomyosin 
arcs are represented as yellow curved lines in the pSMAC. Centripetal movement of microclusters is represented by 
black arrows. Figure inspired by Alarcón et al (27). 
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2.2 Signaling at the IS 
Antigen recognition by the TCR and engagement of costimulatory and adhesion molecules 
triggers signaling through different pathways that lead to T cell activation and regulation of 
gene expression (Figure I3).  
 
Binding of the MHC/antigen to the TCR induces TCR/CD3 clustering and a conformational 
change in the CD3 chains, which result in the recruitment of adaptors and protein tyrosine 
kinases (28, 29).  Phosphorylation of the immunotyrosine-based activation motifs (ITAMs) of 
CD3 chains by the leukocyte C-terminal Src kinase (Lck), which is activated by the phosphatase 
CD45 (30), results in the recruitment of proteins containing SH2 domains, such as ZAP70 (31). 
Once activated by Lck, ZAP70 phosphorylates the scaffolds protein linker for activation of T 
cells (LAT) and SLP76, which leads to the formation of a molecular complex with the adaptors 
SLP76, Grb2-Related Adaptor Downstream of Shc (GADS) and Nck (non-catalytic region of 
tyrosine kinase), the guanine nucleotide exchange factor (GEF) Vav1, and the interleukin-2-
inducible tyrosine kinase (Itk) (Figure I3A). Costimulation by CD28 also contributes to the 
formation of this molecular complex. CD28 induces signaling via Vav1/SLP76 complexes 
through interaction with growth factor receptor-bound protein 2 (Grb2) (32). In addition, CD28 
promotes phosphatidylinositol 3 kinase (PI3K) recruitment and activation at the IS (33). PI3K 
converts membrane-bound phosphatidylinositol 4,5-biphosphate (PIP2) to phosphatidylinositol 
(3,4,5) triphosphate (PIP3). PIP3 then serves as a docking site for Itk, keeping it close to Lck and 
hence facilitating Lck-mediated activation of Itk (34) (Figure I3A). 
 
The signaling complex formed around LAT recruits phospholipase C γ 1 (PLCγ1), which is 
activated by Itk (Figure I3B). Active PLCγ1 catalyzes the hydrolysis of PIP2 into the secondary 
messengers diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). IP3 generated by active 
PLCγ1 drives intracellular calcium raise. Increased calcium levels activate calcineurin and 
induce the nuclear translocation of nuclear factor of activated T cells (NFAT) that, together 
with activator protein-1 (AP-1) and nuclear factor κ B (NF-κB), induce gene expression changes 
upon T cell activation  (35, 36). On the other hand, local accumulation of DAG triggers the 
activation of PKCθ, which, together with the microtubule motor dynein, drives MTOC 
polarization to the IS (18, 37, 38). Besides, DAG promotes the polarization and activation of 
Ras, triggering the activation of the MAPK (mitogen-activated protein kinase) Erk1/2 
(extracellular signal activated kinase 1/2) (39). Other members of the MAPK signaling module 
are also activated downstream the TCR (Figure I3B). Activation of p38 upon T cell stimulaton 
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has been proposed to occur through activation of the classical MAPK cascade by Vav1 and the 
Rho-family GTPase Rac (40), but also through an alternative pathway involving direct 
phosphorylation of p38 by ZAP70 (41). Both pathways seem to coexist in T cells (42). The 
mechanism of activation of the c-Jun N-terminal kinase (JNK) during T cell activation requires 
CD28 costimulation (43), and seems to involve Rac and PKCθ (44, 45).  
 
 
 
Figure I3. Signaling at the IS. The main signaling pathways induced downstream the TCR and costimulatory 
molecules are schematised. A. Initial steps of TCR and CD28 signaling leading to formation of a molecular complex 
around LAT and Itk activation. B. Signaling events downstream LAT/Itk leading to regulation gene expression and 
MTOC polarization. (A to B) Grey arrows indicate activation. Light blue arrows indicate phosphoinositide 
modifications. Red arrows indicate induction of cellular processes. 
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As mentioned before, the integrin LFA-1 expressed on the T cell surface binds its ligand 
intercellular adhesion molecule 1 (ICAM-1) on the APC, providing adhesive forces that stabilize 
the IS. In addition, LFA-1 acts as a costimulatory molecule by activating SLP76 (46), inducing 
signaling trough Erk1/2 (47) and PI3K (48), and contributing to AP-1 transcriptional regulation 
(49). 
  
 
2.3 Regulation of actin polymerization at the IS 
Actin polymerization at the IS is regulated by several signaling pathways that converge from 
the TCR, the costimulatory molecules, and integrins. The GEF Vav1, present at signalling 
complexes downstream the TCR, CD28 and LFA-I, activates the Rho family GTPases CDC42 and 
Rac1, that, in turn, activate the actin nucleation factors WASp (Wiskott Aldrich syndrome 
protein) and Wave2, respectively (48, 50) (Figure I4). Indeed, both proteins have been shown 
to be recruited to the IS (51), where Wave2 is important for lamellipodium formation (52). 
Together with the hematopoietic lineage cell-specific protein 1 (HS1), which is phosphorylated 
downstream TCR signaling (53), WASp and Wave2 promote actin polymerization through actin-
related protein 2/3 (ARP2/3) complex (54, 55) (Figure I4). However, proper actin 
depolymerization is also required to maintain actin dynamics at the IS. The protein cofilin 
severs actin filaments and depolymerizes F-actin, providing new barbed ends that serve as 
substrates for elongation factors (56). It has been shown that cofilin activity is required for 
proper IS formation and T cell activation (57). Cofilin is activated upon T cell stimulation 
downstream Ras and PI3K (58), in a mechanism that could also involve the phosphatase 
Slingshot 1 (SSH1), which specifically dephosphorylates cofilin (59, 60) (Figure I4). Cofilin 
activation is counteracted by LIM kinase (LIMK), which inhibits cofilin by phosphorylation (61) 
downstream the small GTPase RhoA and the Rho-associated protein kinase (ROCK) (62) (Figure 
I4). Hence, a highly regulated balance between actin polymerization and depolymerization has 
to be maintained for proper T cell signalling progression and T cell stimulation. 
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Figure I4. Regulation of actin dynamics at the IS. The main signaling pathways regulating actin dynamics at the IS 
are schematised. Grey arrows indicate activation. Red line indicates inhibition. Orange arrows indicate dynamics of 
actin.  
 
3. Subsets of effector Th cells 
 
Upon antigen recognition, naïve CD4 T cells differentiate into effector Th cells, which will be 
able to respond faster and with higher magnitude in subsequent stimulations by APCs. At least 
four effector Th subsets or lineages have been described: Th1, Th2, Th17 and Treg (Figure I5) 
(7). Differentiation into (or polarization to) one of these subsets is initiated by signaling of 
cytokines present in the environment at the moment of antigen presentation and stabilized by  
a lineage-specifying transcription factor through epigenetic mechanisms (1). Once 
differentiated, each Th subset will produce distinct signature cytokines and exert different 
effector functions (Figure I5). Although the factors driving polarization to each Th subset are 
well known (7), the structure and dynamics of the underlying molecular networks remain to be 
fully elucidated. The four main Th subsets are briefly described below. 
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Figure I5. Th subsets. The four main subsets of Th cells and the cytokines driving their differentiation are shown in 
the upper part. The main transcription factor and STAT protein involved in each subset commitment are depicted 
inside each Th cell. The cytokines produced and the physiological function of each subtype are shown in the lower 
part of the scheme. 
 
 
3.1 Th1 and Th2  
Th1 cells produce interferon γ (IFNγ) and IL-2, and mediate immune responses against 
intracellular pathogens (7). Th1 polarization is initiated by the cytokine IL-12 through activation 
of the transcription factor signal transducer and activator of transcription (STAT) 4, and 
amplified by IFNγ-mediated activation of STAT1. These pathways converge in the induction of 
the master regulator of Th1 polarization, the transcription factor Tbet (63, 64).  
 
Th2 cells produce IL-4, which induces B cell switching to IgE production, and IL-5, which 
recruits eosinophils (7). Hence, Th2 responses are predominant in allergy and helminthic 
infections (65). Th2 polarization is promoted by IL-4 through activation of STAT6 (66), which 
induces the master regulator of Th2 differentiation, GATA-binding protein 3 (GATA3) (67). Th2 
polarization has also been shown to be promoted by antigens with weak affinity, which seem 
to induce GATA3 activation and IL-4 production (68, 69). 
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The distribution of cytokine receptors during the IS has been proposed to be a mechanism for 
controlling Th1 and Th2 differentiation. It has been reported that in absence of exogenous 
cytokines the IFNγ receptor (IFNγ-R) is recruited to the IS in naïve cells upon TCR activation, 
while IL-4 receptor is not. By contrast, when IL-4 was added during TCR stimulation, IFNγ-R 
recruitment was blocked in a STAT6-dependent manner (70). In addition, phosphorylated 
(active) STAT1 was corecruited with the TCR and the IFNγ-R at the IS in absence of IL-4 (71). 
Hence, the differential recruitment of cytokine receptor to the IS would determine the 
predominant cytokine signals received by the T cell during antigenic stimulation and, 
consequently, Th1/Th2 commitment. These findings highlight the importance of spatial 
regulation at the IS in determining T cell responses. In addition, these evidences also suggest 
that naïve CD4 T cells are prone to differentiate to Th1 cells instead of the other Th 
phenotypes, a notion supported by other groups (72). 
 
3.2 Th17 
Th17 cells produce IL-17, which triggers neutrophil recruitment, being important in the 
defense against fungi (7). IL-17 also triggers inflammation, and has a pathogenic role in 
autoimmunity (73). Th17 cells differentiate in presence of IL-1β, IL-6 and IL-23 (74), which 
signal through STAT3 to induce IL-17 production (75). Some groups have reported that 
transforming growth factor β (TGF-β) is also required for Th17 cell polarization (76), although 
other studies sustain that it is not (74). The master regulator of Th17 cells is the RAR-related 
orphan receptor γt (RORγt) (77). 
 
3.3 Treg 
T regulatory (Treg) cells produce IL-10 and TGF-β, and exert anti-inflammatory functions (78). 
Treg cells differentiate in presence of IL-2 and TGF-β (7), which induces the expression of the 
master regulator of Treg differentiation, the transcription factor Forkhead box P3 (Foxp3) (79, 
80). The action of STAT5 is also required for Foxp3 expression (81). In addition, strong TCR 
signals have been shown to inhibit Foxp3 and as a consequence Treg differentiation (82). 
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4. Protein tyrosine phosphatases 
 
As explained in the preceding sections, signaling downstream the TCR and costimulatory 
molecules occurs through a cascade of phosphorylation events that is tightly regulated by 
kinases and phosphatases. In fact, treatment of Jurkat cells with pervanadate, a potent 
inhibitor of protein tyrosine phosphatases (PTPs) (83), results in induction of proximal TCR 
signaling and production of IL-2, mimicking TCR crosslinking (84). Hence, the experiments with 
pervanadate show that, in general, tyrosine phosphatases are important for maintaining T cells 
in the resting state in absence of antigenic stimulation. This does not mean, however, that all 
the tyrosine phosphatases are negative regulators of signaling downstream the TCR. In fact, 
some PTPs such as CD45 are required for T cell activation (85), while others such as the low-
molecular-weight PTP (LMPTP) positively regulate signaling downstream the TCR (86). T cells 
express a high number of the more than a hundred PTPs present in the human genome (87, 
88), but the role of the majority of them during T cell stimulation and IS assembly has not been 
addressed.   
 
4.1 Classification of the PTP superfamily  
In humans there are 107 genes that encode members of the PTP superfamily, based on their 
conserved catalytic motifs and PTP domains (87). It is important to note that a large number of 
the so-called PTPs are able to dephosphorylate serine (Ser) and threonine (Thr) in addition to 
tyrosine (Tyr) residues, while others can dephosphorylate messenger ribonucleic acid (mRNA) 
or phospholipids. Besides, there are catalytically inactive PTPs that exert functions non-
dependent on dephosphorylation (89-91). Hence, the PTP superfamily includes members with 
different substrate specificities that can regulate a broad range of cellular processes. In 
addition, the members of the PTP superfamily are heterogeneous in their subcellular 
localization, ranging from transmembrane receptor-like proteins, to enzymes localized in 
cytosolic, endosomal, and nuclear compartments. PTPs can be classified in four classes based 
on the sequences of their catalytic domains (Figure I6). Class I, II and III PTPs base their 
catalytic mechanism in a residue of cysteine (Cys), while the catalytic residue in Class IV is an 
aspartic acid (Asp). The four classes have evolved independently, and Class II and III seem to be 
more ancient than class I, having evolved from bacterial enzymes. Class I is the largest, with 99 
members, and can be further divided in two groups: classical PTPs, which are specific for Tyr 
residues, and dual specific phosphatases (DSPs), able to dephosphorylate a wide range of 
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substrates. Classes II, III and IV, in contrast, consist of 1, 3 and 4 members, respectively (Figure 
I6). Here we will refer DSPs and PTPs from classes II, III and IV as non classical (NC) PTPs.  
 
         
 
Non classical (NC) PTPs  
 
 
 
Figure I6. Classification of the PTP superfamily into four classes. The 
numbers in brackets indicate the number of PTPs in each subgroup. 
Figure based on Alonso et al  (87). 
 
 
4.1.1 Classical PTPs 
The group of classical PTPs, formed by 38 members, is a well-known group of enzymes specific 
for Tyr residues. It can be divided in two subgroups, the receptor type PTPs (RPTPs), such as 
CD45, which have a transmembrane domain, and the nonreceptor PTPs (NRPTPs), which are 
intracellular.  
 
4.1.2 DSPs 
The group of DSPs is the more diverse in terms of substrate specificity and its 61 members can 
be further divided in seven subgroups: 
- MAP kinase phosphatases (MKPs): these enzymes have specific MAPK targeting motifs, 
and can dephosphorylate both Tyr and Thr residues. There are ten catalytically active 
MKPs in humans: the ERK-selective cytoplasmic DUSP6, DUSP7 and DUSP9, the JNK/p38-
selective DUSP8, DUSP10 and DUSP16, and the nuclear DUSP1, DUSP2, DUSP4 and DUSP5, 
which also dephosphorylate ERK. In addition, the phosphatase dead (PD) MK-STYX is also 
classified in this group (92).  
- Atypical DSPs: the nineteen enzymes that form this group lack specific MAPK targeting 
motifs and can dephosphorylate either Tyr or Thr residues, with the exception of PIR1, 
which dephosphorylates mRNA (93), Laforin, which dephosphorylates glycogen (94), the 
mRNA capping enzyme RNGTT,  and the PD STYX.  
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- Slingshots (SSHs): this group includes three enzymes (SSH1, SSH2 and SSH3), that 
dephosphorylate and consequently activate cofilin in Ser, and that have actin-bundling 
activity (60). 
- Phosphatases of regenerating liver (PRLs): this group includes three enzimes (PRL-1, PRL-2 
and PRL-3, enconded by the genes PTP4A1, PTP4A2 and PTP4A3, respectively) with 
unknown substrates that have been implicated in cancer progression (95). 
- Cell division cycle-14 proteins (CDC14s): the members of this group (CDC14A, CDC14B and 
CDKN3) inactivate cyclin-dependent kinases (CDKs) to induce mitotic exit and are also 
involved in mitotic spindle formation (96, 97). 
- Phosphatase and tensin homologs (PTENs): this group is formed by five members, four of 
which are active phosphatases that dephosphorylate the position 3 of phosphoinositides 
(98).   
- Myotubularins (MTMs): the members of this group dephosphorylate the position 3 of 
PI3P and PI(3,5)P2 (98). Among the sixteen members of this group, nine are catalytically 
active, while the other seven are thought to be PD enzimes that bind to the active 
members of the group, regulating their activity (91). 
 
4.1.3 Class II Cys-based PTPs 
This class is composed by only one member, LMPTP, encoded by the gene ACP1. LMPTP is able 
to dephosphorylate Tyr residues, but not Ser o Thr (99), and in T cells has been described to 
dephosphorylate ZAP70 (86) and focal-adhesion kinase (FAK) (100).  
 
4.1.4 Class III Cys-based PTPs 
This group is formed by the three cell division cycle-25 proteins (CDC25s): CDC25A, CDC25B 
and CDC25C, that dephosphorylate cyclin-dependent kinases (CDKs) in Tyr and Thr residues, 
promoting entry into mitosis (101). 
 
4.1.5 Asp-based PTPs 
The eyes absent (Eya) phosphatases that form this class have the peculiarity of using an Asp as 
catalytic residue to dephosphorylate their substrates in Tyr (102, 103). Eya phosphatases are 
encoded by four genes in humans (Eya1, Eya2, Eya3 and Eya4) and act as transcriptional 
regulators during organogenesis (103, 104). 
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4.2 PRLs 
The first PRL identified was PRL-1, and was given its name because it was found as a gene 
induced in rats upon hepatectomy (105, 106). Mouse PRL-2 and PRL-3 were identified later as 
proteins with high homology to PRL-1 (107). The most relevant features of PRLs will be 
outlined below.   
 
4.2.1 Structure, regulation and substrate specificity 
The PRLs are relatively small proteins of around 19 KDa, although according to the Gene 
database (NCBI), smaller isoforms of PRL-2 and PRL-3 exist in humans. Considering the full-
length isoform, the aminoacid identity between the three human PRLs is very high (Figure I7):  
87% between PRL-1 and PRL-2, 79% between PRL-1 and PRL-3, and 76% between PRL-2 and 
PRL-3 (95). The motifs of the PRLs and their localization are highlighted in the sequences 
shown in Figure I7.   
 
The PTP domain contains the active site, which shares the common PTP signature motif 
(I/V)HCXXGXXR(S/T) (108). This sequence contains the catalytic Cys (Cys 104 in PRL-1 and PRL-
3, Cys 101 in PRL-2), which exerts a nucleophilic attack to the phosphate group on the 
substrate creating a cysteinyl-phosphate intermediate (109). Release of the dephosphorylated 
substrate requires the participation of an Asp (Asp 72 in PRL-1 and PRL-3, Asp 69 in PRL-2), 
situated in the adjacent WPD loop (110). Unlike other PTPs, however, PRLs have an Alanine 
instead of the Ser/Thr at the end of the active site, and this difference might be the cause of 
the low activity of PRLs in vitro (110, 111). Next to the PTP domain is found a polybasic region 
(Figure I7) that has been reported to contribute to localization of PRL-1 at the inner face of the 
plasma membrane (112). Finally, the CAAX motif situated in the C-terminal region of the PRLs 
provides a signal for farnesylation on the first Cys (113) that is required for subcellular 
distribution of PRLs at the plasma membrane and endosomes  (112, 114-116). It has been 
reported that the second Cys of the CAAX motif of PRL-3 can be palmitoylated, a modification 
that could reversibly regulate the subcellular distribution of the molecule (117). Whether 
palmitoylation also takes place in PRL-1 and PRL-2 remains to be determined. 
 
Redox regulation of these proteins has been proposed (118), and for PRL-1, reversible 
oxidation of the catalytic Cys has been shown to inactivate the protein in mammalian retina 
(119). Another mechanism for regulation of PRL localization and activity might be the 
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formation of trimers, as shown for PRL-1 (Figure I7B) (112, 120). The structure of the trimer 
positions the CAAX motif of each monomer in the upper side of the trimer, allowing for binding 
to membranes, while the regions involved in catalysis (the WPD loop and the catalytic motif) 
remain at the outer face of the trimer, leaving space for substrate binding in each monomer. 
 
 
 
Figure I7. Structure of the PRLs. A. The alignment of the amino acid sequences of the three PRLs is shown. Motifs 
are highleted by squares. The number of the last aminoacid of each row is indicated on the righ. Asterisks indicate 
identic residues. The alignment was performed with the MAFFT version 7 software. B. Ribbon diagram of the 
tridimensional structure of the trimer formed by PRL-1 as described by Jeong and coworkers (120). In each 
monomer, the WPD loop (green), the catalytic motif (purple), the polybasic region (red) and the CAAX motif (yellow) 
are highlighted. Tridimensional structures were obtained from the Protein Data Bank and represented using Pymol 
software. 
 
 
The substrates of the PRLs are currently unknown (95), and the study of their structure has not 
provided clues of their substrate specificity. In fact, the phosphatases structurally most closely 
related to PRLs are PTEN, vaccinia H1-related phosphatase (VHR or DUSP3), and CDC14s, but, 
compared with them, PRLs lack regions important for substrate recognition (95, 120). In 
addition, these related phosphatases show different substrate specificities, ranging from 
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phosphoinositides (PTEN) (98), to Tyr (VHR) (121) and Ser/Thr (CDC14s) (122, 123). The only 
substrate proposed for PRL-1 is the activating transcription factor 7 (ATF-7), although 
interaction between the two proteins and dephosphorylation of ATF-7 by PRL-1 has been 
reported only in vitro (124). Regarding PRL-3, it has been proposed to dephosphorylate ezrin 
(125) and PI(4,5)P2 (126), although further confirmation will be needed to identify these 
molecules as canonic substrates of PRL-3. 
 
4.2.2 Expression 
In normal adult tissues, PRL-1 and PRL-2 are ubiquitously expressed, showing detectable 
expression in a wide range of tissues and cell types, including lymph nodes, thymus, and 
peripheral blood lymphocytes (127, 128). However, their role in lymphocyte activation has not 
been addressed. PRL-3 mRNA is expressed mainly in normal skeletal muscle, heart, and 
pancreas (129), as well as in developing blood vessels and pre-erythrocytes (130). In the 
hematopoietic system, PRL-2 has the highest expression among PRLs, followed by PRL-1, while 
the expression of PRL-3 is very low (131).  In addition, the three PRLs are upregulated in 
several cancer types. Both PRL-1 and PRL-2 have been shown to be overexpressed in cancer 
cell lines when compared with untransformed cells (114, 132). PRL-3, the most studied PRL in 
this regard, is upregulated in several cancer types, including breast, gastric, and ovarian 
carcinomas, where PRL-3 overexpression correlates with poor prognosis (133-135). 
Overexpression of PRLs has also been described in hematological malignancies (131). Hence, it 
was soon recognized that the three PRLs promote tumor progression, invasion, and 
metastasis.  
 
4.2.3 PRLs in intracellular signaling and function 
PRLs promote cell proliferation, migration and invasion, having oncogenic properties (136). 
Several signaling pathways and cellular processes have been shown to be affected by these 
proteins, some of which seem to explain their oncogenicity. Firstly, PRLs induce cell migration 
and invasion. In fact, knock down or inhibition of the catalytic activity of PRLs decreased 
p130Cas phosphorylation and protein levels in cancer cells, resulting in less anchorage-
independent tumor cell growth (137). p130Cas is a scaffold protein that participates in 
migration and invasion downstream the oncogenic protein Src (138). Consistently, 
overexpression of PRL-1 increased Src and p130Cas phosphorylation in HEK-293 cells (139). 
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Secondly, PRLs promote cell survival and proliferation through several signaling pathways. The 
three PRLs have been shown to induce ERK1/2 activation in cancer cells (132, 139, 140), 
although the mechanism remains to be determined. Interestingly, it has been proposed that 
PRL-1-mediated activation of ERK1/2 takes place through binding of PRL-1 to the MEKK1 
inhibitor p115 RhoGAP (141). Whether PRL-2 and PRL-3 act through the same mechanism 
remains to be determined. In addition, PRL-3 induces PI3K/Akt signaling in cancer cell lines 
(142), an effect that might be mediated by downregulation of PTEN levels (143).  
 
In physiological conditions, PRLs also seem to regulate cell proliferation. In fact, PRL-1 localizes 
to the centrosome and the mitotic spindle, where it regulates normal mitosis (114), while PRL-
2 promotes cell proliferation in mouse placenta by activating the Akt kinase through 
downregulation of the tumor suppressor PTEN (144). Interestingly, PRL-2 seems to be 
important in the development of the hematopoietic system. Analysis of knockout mice for PRL-
2 has shown that this PRL is required for hematopoietic stem cell self-renewal, since it 
promotes proliferation of hematopoietic stem cells (145). In addition, loss of PRL-2 decreases 
lymphocyte count in peripheral blood and blocks development of T lymphocytes at the double 
negative stage (131, 145). Recently, it has also been shown that PRL-2 is an effector of the 
Notch signaling pathway in T cell progenitors, being required for generation and maturation of 
T cells (146). These findings point to important roles of PRLs not only during cancer 
progression, but also in normal tissues.  
 
Several findings suggest the PRLs might be involved in the organization of the actin 
cytoskeleton through regulation of Rho GTPases. In fact, it has been shown that 
overexpression of PRL-1 or PRL-3 leads to inhibition of Rac and activation of RhoA and RhoC 
(116, 147), while silencing of PRL-1 decreases Rac and Cdc42 activation in cancer cells (148).  
 
The reported role of PRLs as regulators of the actin cytoskeleton, together with the reported 
expression of PRL-1 and PRL-2 in lymphocytes, suggest that PRLs could be regulators of IS 
assembly and T cell signaling. 
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HYPOTHESIS AND OBJECTIVES 
 
PTPs are key regulators of phosphorylation levels, which control T cell activation and 
differentiation. Although T cells express a high number of NC PTPs, the role of the majority of 
these enzymes in T cell activation and differentiation is unknown. Our hypothesis was that 
some NC PTPs are yet unknown regulators of T cell activation and differentiation. We payed 
particular attention to PRLs due to their regulatory role on actin dynamics reported in the 
literature.  
The general aim of this work was to study the changes in the expression of NC PTPs during T 
cell responses and the role of the PRLs during IS assembly and T cell activation. To address this 
general aim, we posed the following specific objectives: 
 
1. To study the changes in the expression profile of NC PTPs during Th1 differentiation and 
restimulation 
 
2. To study the expression of PRLs during T cell activation 
 
3. To study the contribution of the catalytic activity of PRLs to T cell activation 
 
4. To study the delivery of PRL-1 to the IS 
 
5. To study the contribution of PRL-1 to T cell activation and its regulatory role in IS assembly 
and signaling downstream the TCR  
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MATERIALS AND METHODS 
 
1. Materials 
 
1.1 Reagents 
 
Table MM1. Reagents 
Product Source 
Agarose Sigma-Aldrich 
Analog 3 Enamine 
AseI New England Biolabs 
Blocking reagent Roche 
Brefeldin A Sigma-Aldrich 
BsrGI New England Biolabs 
CellTracker™ Blue CMAC Dye Molecular probes 
Distilled water Gibco 
DMEM w/o phenol red Lonza 
Dynabeads Human T-Activator CD3/CD28 Gibco 
E Superantigen (SEE) Toxin Technology 
EDTA Panreac 
Fetal Calf Serum (FCS) Gibco 
Hepes Gibco 
Homology arms (HA DNA) IDT 
Human IgG Sigma-Aldrich 
ICAM-Fc Carlos Cabañas, PhD 
ImmunoCult™ Human CD3/CD28 T Cell Activator StemCell technologies 
Ionomycin Sigma-Aldrich 
L-Glutamine Lonza 
Latex beads Sigma-Aldrich 
LymphoprepTM Rafer 
MluI New England Biolabs 
Mouse serum Sigma-Aldrich 
NheI New England Biolabs 
Non-essential aminoacids Gibco 
Paraformaldehyde Sigma-Aldrich 
PCR Nucleotide Mix Roche 
PCR Reaction Buffer, 10X Roche 
Penicillin 10000 U/mL-Streptomycin 10000 µg/mL  Lonza 
Phalloidin-488  Molecular Probes 
Phosphate buffered saline (PBS) Gibco 
Phorbol 12-myristate 13-acetate Sigma-Aldrich 
Pierce
TM
 ECL Plus Substrate Thermo Scientific 
Poly-L-Lysine Sigma-Aldrich 
Procyanidin B3 (PB3) ChemFaces 
Recombinant human IL-12 Preprotech 
RPMI 1640 Lonza 
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Table MM1. Reagents (continuation) 
Product Source 
Saponin Sigma-Aldrich 
Sodium pyruvate Gibco 
SpeI New England Biolabs 
Taq DNA polymerase Roche 
Taqman® gene expression  master mix Applied Biosystems 
Thienopyridone (TP) Enamine 
TMB Calbiochem 
Triton X-100 Sigma-Aldrich 
Trizma® base Sigma-Aldrich 
T4 DNA Ligase New England Biolabs 
U0126 Cell Signaling 
XhoI New England Biolabs 
 
1.2 Kits 
 
Table MM2. Kits  
Product Source 
Amersham Cy3 mAb Labelling Kit GE Healthcare 
Amaxa
TM
 Human T Cell Nucleofector
TM
 Kit Lonza 
Amaxa
TM
 Cell Line Nucleofector
TM
 Kit V Lonza 
Dynabeas
TM
 untouched
TM
 Human CD4 T cells kit Invitrogen 
Human IL-2 ELISA Set BD OptiEA 
Naïve CD4+ T cell Isolation Kit II Miltenyi 
Absolutely RNA Microprep Kit Agilent Technologies 
Illustra
TM
 DNA Extraction Kit BACC2 GE Healthcare 
QIAquick Gel Extraction Kit QIAGen 
 
1.3 Primers 
1.3.1 Primers for PCR (Sigma-Aldrich) 
 
Table MM3. Primers for PCR 
Target Application Sequence Forward (5'-3') Sequence Reverse (5'-3') 
5'HA-GFP Amplification AAAGAAAACAACTATCGAAAGGG GGTGCAGATGAACTTCAGGGTC 
GFP-3'HA Amplification TCAAGGTGAACTTCAAGATCCG TGAGATCATGCCACTGCACTC 
5'HA-GFP Sequencing CAAAAATGTAACAATGGGTTTGG GCTGAACTTGTGGCCGTTTACG 
GFP-3'HA Sequencing GACAACCACTACCTGAGCACCC GACAGAACGAGACTCCATCTC 
 
 
 
 
MATERIALS AND METHODS 
 
53 
 
1.3.2 TaqMan assays for qPCR and Low-Density Arrays (Applied Biosystems) 
Table MM4. TaqMan assays 
Target Assay number Target Assay number 
Gene Protein  Gene Protein  
CDC14A CDC14A Hs00186432_m1 MTMR4 MTMR4 Hs00608314_m1 
CDC14B CDC14B Hs00372920_m1 MTMR5 SBF1 Hs00959744_g1 
CDC25A CDC25A Hs00947994_m1 MTMR6 MTMR6 Hs00395064_m1 
CDC25B CDC25B Hs00244740_m1 MTMR7 MTMR7 Hs00952738_m1 
CDC25C CDC25C Hs00156411_m1 MTMR8 MTMR8 Hs00250307_m1 
CDKN3 KAP Hs00193192_m1 MTMR9 MTMR9 Hs00209995_m1 
CD69 CD69 Hs00934033_m1 MTMR10 MTMR10 Hs01107504_m1 
DUSP1 MKP1 Hs00610256_g1 MTMR11 MTMR11 Hs00916722_m1 
DUSP2 PAC-1 Hs01091226_g1 MTMR12 MTMR12 Hs00539666_m1 
DUSP3 VHR Hs01115776_m1 MTMR13 SBF2 Hs00293588_m1 
DUSP4 MKP-2 Hs01027785_m1 MTMR14 MTMR14 Hs00560430_m1 
DUSP5 DUSP5 Hs00244839_m1 MTMR15 MTMR15 Hs00429686_m1 
DUSP6 MKP-3 Hs04329643_s1 PTEN PTEN Hs02621230_s1 
DUSP7 MKP-X Hs00997002_m1 PTPDC1 PTPDC1 Hs01115183_m1 
DUSP8 DUSP8 Hs00792712_g1 PTPN1 PTP1B Hs00942477_m1 
DUSP9 MKP-4 Hs01046584_g1 PTPN2 TCPTP Hs00959886_g1 
DUSP10 MKP-5 Hs00200527_m1 PTPN4 PTP-MEG1 Hs00267762_m1 
DUSP11 PIR1 Hs01061375_m1 PTPN6 SHP1 Hs00169359_m1 
DUSP12 DUSP12 Hs00170898_m1 PTPN7 HePTP Hs00978680_m1 
DUSP13 DUSP13 Hs00969203_m1 PTPN9 PTP-MEG2 Hs00361739_m1 
DUSP14 MKP-6 Hs01877076_s1 PTPN12 PTP-PEST Hs00184747_m1 
DUSP15 VHY Hs01566654_m1 PTPN13 PTP-BAS Hs01106214_m1 
DUSP16 MKP-7 Hs00411837_m1 PTPN18 PTP20 Hs01079757_g1 
DUSP18 DUSP20 Hs01036622_g1 PTPN22 LYP Hs01587518_m1 
DUSP19 DUSP17 Hs00369901_m1 PTPRA RPTPα Hs00160751_m1 
DUSP21 DUSP21 Hs00254403_s1 PTPRC CD45 Hs04189704_m1 
DUSP22 VHX Hs00414885_m1 PTPRJ CD148 Hs01119326_m1 
DUSP23 DUSP23 Hs00367783_m1 PTPRK RPTPκ Hs00267788_m1 
DUSP26 VHP Hs00225167_m1 PTP4A1 PRL-1 Hs00743856_s1 
DUSP27 DUSP27 Hs01367756_m1 PTP4A2 PRL-2 Hs00754750_s1 
EPM2A Laforin Hs00194655_m1 PTP4A3 PRL-3 Hs02341135_m1 
EYA1 Eya1 Hs00166804_m1 RNGTT RNGTT Hs01016926_m1 
EYA2 Eya2 Hs00193347_m1 SSH1 SSH1 Hs00368014_m1 
EYA3 Eya3 Hs00544914_m1 SSH2 SSH2 Hs00810681_m1 
EYA4 Eya4 Hs00187965_m1 SSH3 SSH3 Hs00215309_m1 
GATA3 GATA3 Hs00231122_m1 STYX STYX Hs00377042_m1 
GNB2L1 GNB2L1 Hs00272002_m1 Tbet TBX21 Hs00203436_m1 
IL-2 IL-2 Hs00174114_m1 TENC1 TENC1 Hs00539247_m1 
MK-STYX MK-STYX Hs01555207_m1 TNS1 Tensin Hs00917032_m1 
MTM1 MTM1 Hs00896978_m1 TPTE PTEN2 Hs04186747_m1 
MTMR1 MTMR1 Hs00395009_m1 TPIP TPIPα Hs01685756_m1 
MTMR2 MTMR2 Hs01547438_m1 18S  Hs99999901_s1 
MTMR3 MTMR3 Hs00221562_m1    
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1.4 Plasmids 
Table MM5. Plasmids 
Plasmid Source 
β-Actin speckle Miguel Vicente-Manzanares, PhD (HUP) 
CD3ζ-mCherry Balbino Alarcón, PhD. (CBMSO) 
GFP C1 (GFP) Clontek 
GFP-PRL-1 Rocío Ramírez, MSc (UCM) 
GFP-PRL-1-ΔCAAX Rocío Ramírez, MSc (UCM) 
GFP-PRL-3 Patricia Castro, MSc (UCM) 
mCitrine-PRL-1 (mCit-PRL-1) Max Planck Institute 
mCitrine-PRL-2 (mCit-PRL-2) Max Planck Institute 
LifeAct RFP Ibidi 
LV C9 Raúl Torres, PhD (CNIO) 
YFP Clontek 
CBMSO, Centro de Biología Molecular Severo Ocha. CNIO, Centro Nacional de Investigaciones 
Oncológicas. HUP, Hospital Universitario de la Princesa. UCM, Universidad Complutense de Madrid. 
 
1.5 Antibodies 
1.5.1 Primary antibodies 
Table MM6. Primary antibodies 
Antigen Fluorophore Clone Host Application Source 
α Tubulin --- DM1A Mouse WB Sigma-Aldrich 
α Tubulin FITC  Mouse IF Molecular Probes 
CD3ε APC HIT3a Mouse FC BD Pharmingen 
CD3ε --- T3b Mouse IF Francisco Sánchez-Madrid, PhD 
CD3ε --- UCHT1 Mouse Stimulation Purified from hybridome 
CD3ζ --- 448 Rabbit IF Balbino Alarcón, PhD 
CD4 PE 13B8.2 Mouse FC Beckman Coulter 
CD19 PerCP A3-B1 Mouse FC Immunostep 
CD28 --- CD28.2 Mouse Stimulation BD Pharmingen 
CD45RA FITC ALB11 Mouse FC Beckman-Coulter 
CD69 APC CH/4 Mouse FC Molecular Probes 
ERK1/2 --- L34F12 Mouse WB Cell Signaling 
ERK1/2-pT202/Y204 ---  Rabbit WB Cell Signaling 
GFP --- Polyclonal Rabbit FC/WB Life Technologies 
IFNγ FITC B27 Mouse FC BD Pharmingen 
PLCγ --- Polyclonal Rabbit WB Cell Signaling 
PLCγ-pY783 --- Polyclonal Rabbit WB Cell Signaling 
PRL-1 ---/Cy3 --- Mouse FC/WB Qi Zeng, PhD 
PRL-1/2 --- 42 Mouse WB Merck 
APC, allophycocyanin. FC, flow cytometry. FITC, fluorescein. IF, immunofluorescence. PE, phycoerythrin. PerCP, peridinin 
chlorophyll protein. WB, western blot. 
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1.5.1 Isotype controls 
 
 
 
                                                                                                                                                                                         FC,
FC, flow cytometry. IF, immunofluorescence 
 
1.5.2 Secondary antibodies 
Table MM8. Secondary antibodies 
Antibody Conjugation Application Source 
Donkey Anti-Mouse  Alexa Fluor 594 IF Life Technologies 
Donkey Anti-Rabbit Alexa Fluor 488 IF Life Technologies 
Goat Anti-Mouse  APC FC Life Technologies 
Goat Anti-Mouse IRDye 680RD WB LICOR 
Goat Anti-Rabbit Alexa Fluor 594 IF Life Technologies 
Goat Anti-Rabbit IRDye 800RD WB LICOR 
Goat anti-Rabbit HRP WB Merck 
FC, flow cytometry. IF, immunofluorescence. WB, western blot 
 
1.6 Buffers 
Table MM9. Buffers 
Buffer Composition 
Carbonate buffer 0,1 M NaHCO3; 32 mM Na2CO3 
IP Lysis buffer 10 mM Tris-HCl pH 7,5; 0,5% NP-40; 150 mM NaCl; 0,5 mM 
EDTA; 1X protease inhibitor cocktail; 10 mM NaF; 1 mM 
PMSF; 1 mM Na3VO4 
RIPA buffer 20 mM Tris-HCl pH 7,5; 1% NP-40; 0,5% sodium 
deoxycholate; 0,1% SDS; 150 mM NaCl; 10 mM β-
glicerophosphate; 1X protease inhibitor cocktail; 10 mM 
NaF; 1 mM PMSF; 1 mM Na3VO4 
TBS 20 mM Tris-HCl pH 7,5; 150 m M NaCl 
TNB TBS + 0,5 % blocking reagent 
WB Lysis buffer 20 mM Tris-HCl pH 7,5; 0.2% Triton X-100; 1% NP-40; 150 
mM NaCl; 2mM EDTA; 1,5 mM MgCl2; 10mM 
Glycerophosphate; 1X protease inhibitor cocktail; 1 mM 
Pyrophosphate; 1 mM NaF; 2 mM Na3VO4; 1 mM PMSF 
 
 
 
 
 
 
Table MM7. Isotype controls 
Fluorophore Clone Host Application Source 
--- MOPC Mouse IF/FC Sigma-Aldrich 
APC B11/6 Mouse FC Immunostep 
PerCP MOPC-21 Mouse FC Immunostep 
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1.7 Equipment 
 
Table MM10. Equipment 
Device Manufacturer 
AM TIRF MC M system Leica 
Amaxa
TM
 Nucleofector
TM 
II system Lonza 
Digital sonifier Branson 
DMI 6000B microscope Leica 
ELx800™ Absorbance Microplate Reader BioTek 
FACSAria III cell sorter BD Biosciences 
FacsCalibur flow cytometer BD Biosciences 
FV-1200 CLS microscope Olympus 
Neon
TM
 transfection system Invitrogen 
7900HT Fast Real-Time PCR System Applied Biosystems 
 
 
2. Methods 
 
2.1 Purification of primary cells 
Peripheral blood from healthy adult donors (< 65 years old) was obtained from buffy coats 
processed at the transfusion centre of the “Comunidad de Madrid”, Spain. Blood was diluted 
five times in phosphate-buffered saline (PBS) and peripheral blood mononuclear cells were 
obtained by centrifugation on LymphoprepTM density gradient for 35 minutes at 600 g. After 
three washes with PBS, cells were counted and used for cell purification. Total CD4 T cells were 
isolated by negative selection using the DynabeasTM untouchedTM Human CD4 T cells kit. Naïve 
CD4 T cells were isolated by negative selection using the Naïve CD4+ T cell Isolation Kit II. 
Purities over 95% were typically obtained as assessed by flow cytometry. 
 
2.2 In vitro Th1 polarization and restimulation 
Naïve CD4 T cells were cultured for 12 days in RPMI 1640 supplemented with 10% fetal calf 
serum (FCS), 100 U/mL penicillin, 100 µg/mL streptomycin and 2mM L-Glutamine in presence 
of Dynabeads Human T-Activator CD3/CD28 and 10 ng/ml of IL-12. Th1 cells were then 
restimulated for 4 hours with 10 ng/mL phorbol 12-myristate 13-acetate (PMA) plus 1 µM 
Ionomycin (Th1-PI). Th1 polarization was assessed by analysing the induction of the master 
regulators Tbet and GATA3 and the production of IFNγ in response to restimulation with PMA 
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and Ionomycin. For analysis of IFNγ production Th1 cells were restimulated in presence of 5 
µg/mL Brefeldin A, and intracellular content of the cytokine was measured by flow cytometry. 
 
2.3 Cell lines and culture 
The B cell line Raji and the T cell line Jurkat clone J77 (149) were cultured in RPMI 1640 
supplemented with 10% FCS, 2 mM L-Glutamine, 100 U/mL penicillin, 100 µg/ml streptomycin, 
1 mM sodium pyruvate and 1x non-essential aminoacids. 
 
2.4 Generation of knock in GFP-PRL-1 J77 cell line 
The genome of Jurkat J77 cells was edited to generate a knock in cell line (KI) expressing a 
chimeric endogenous GFP-PRL-1 protein (where GFP is the green fluorescent protein), using 
the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 technology (150-
152). Two single guides (Sg) specific for PRL-1 gene targeting (Figure MM1A) were designed by 
Raúl Torres at Centro Nacional de Investigaciones Oncológicas (CNIO, Madrid, Spain) and 
cloned into the pLV C9 plasmid using restriction sites BsrGI and SpeI. This expression vector 
allows for the ectopic expression of the Cas9 endonuclease under the cytomegalovirus 
promoter and of the Sg RNA under the U6 promoter. The Sg RNA is complementary to a region 
of around 20 base pairs (bp) on the target gene, called protospacer. To allow Cas9 recognition, 
the protospacer has to be followed by a protospacer adjacent motif (PAM) with the NGG 
sequence (where N is any nucleotide and G is guanine). Hence, the Cas9 is recruited to the 
gene of interest, where it performs a double strand break (DSB) three nucleotides upstream 
the PAM. In the absence of a donor DNA (deoxyribonucleic acid), this DSB will be repaired by 
non homologous end joining, but if a donor DNA is provided, homologous recombination will 
take place. To promote homologous recombination we generated a donor DNA (Figure 
MM1B). The expression vector GFP C1 was digested with AseI and NheI restriction enzimes to 
eliminate the promoter region of the GFP gene. A 5’ homology arm (5’HA) containing the 685 
bp upstream the start codon of genomic PRL-1 was digested with AseI and NheI and inserted 
replacing the promoter region of GFP gene in the GFP C1 plasmid. Both the generated 5’HA-
GFP plasmid and a 3’ homology arm (3’HA), containing the 677 bp downstream the start codon 
of genomic PRL-1 were then digested with XhoI and MluI and ligated. The generated vector 
5’HA-GFP-3’HA (Figure MM1B, right) allows for the insertion of the open reading frame of the 
GFP upstream of, and in phase with, PRL-1 gene. The resulting edited gene encodes an 
endogenous chimeric GFP-PRL-1 protein (Figure MM1B, left). 
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Jurkat J77 cells were electropored using NeonTM transfection system with the parameters: 
1,325 v, 10 ms, 3 pulses. Transfected cells were maintained in culture until GFP-PRL-1 
expression was detected by flow cytometry. Then, edited cells (GFP+) were sorted using a 
FACSAria III cell sorter. 
 
 
 
 
Figure MM1. Strategy for generation of a KI GFP-PRL-1 cell line. A. Two vectors carrying the gene coding for the 
Cas9 nuclease and one single guide each (Single Guide 1 or 2) were generated. Each Single guide was 
complementary to a sequence in the second exon of genomic PRL-1 (region called protospacer), followed by a PAM. 
Cas9 performs a DSB three nucleotides upstream the PAM (red arrowheads). B. After DSB, homologous 
recombination using the donor DNA takes place. As a result, the GFP cassette is inserted upstream the starting 
codon for PRL-1 (ATG), generating a GFP-PRL-1 coding sequence. 
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2.5 Cell transfection 
Cells were nucleofected using the AmaxaTM NucleofectorTM II system. The Jurkat clone J77 was 
nucleofected using AmaxaTM Cell Line NucleofectorTM Kit V. Two million cells were nucleofected 
with 4 μg of plasmid using program X-001. Primary CD4 T cells were nucleofected using 
AmaxaTM Human T Cell NucleofectorTM Kit. 5-10 million cells were nucleofected with 5 μg of 
plasmid using program U-014. 24 hours after transfection, living cells were isolated by 
centrifugation on LymphoprepTM before further experimental procedures.  
 
2.6 Cell stimulation 
For PRL-1 and PRL-2 expression studies, CD4 or Th1 cells were stimulated for 10, 30, 60, 120 
and 240 minutes with 10 ng/mL PMA plus 1 µM Ionomycin. 
 
For CD69 and IL-2 induction, J77 cells, transfected with either pOPIN N mCitrine-PRL-1 (mCit-
PRL-1) or YFP, were mixed with Raji cells loaded or not with the indicated concentration of 
staphylococcal enterotoxin E superantigen (SEE), at a cell ratio 1:1. Mixtures were cultured 
O/N and stained for flow cytometry analysis. CD4 T cells were stimulated for 6h with 
Dynabeads™ Human T-Activator CD3/CD28 at a ratio 1:1. When specified, cells were 
preincubated for 1 hour with the indicated inhibitor before stimulation. The inhibitors used 
were Thienopyridone (TP, 20 µM), Analog 3 (A3, 75 µM), Procyanidin B3 (PB3, 12,5 to 75 µM) 
and U0126 (20 µM). The inhibitors were maintained during the whole stimulation time. Cells 
were then washed and stained for flow cytometry data acquisition. Supernatants of cell 
cultures were collected for analysis of IL-2 production by Enzyme-Linked Immunosorbent Assay 
(ELISA). 
 
For Western Blot analysis, Raji cells were loaded with SEE (1 µg/mL), washed and mixed with 
J77 cells at 1:10 (RAJI:J77) ratio. Cell mixtures were incubated for 0, 5, 15 or 30 minutes at 
37ºC. Primary CD4 T cells were stimulated with ImmunoCult™ Human CD3/CD28 T Cell 
Activator for the same time as J77 cells. When needed, cells were preincubated for 1 h with 50 
µM PB3 which was maintained during the whole stimulation time. 
 
2.7 Conjugation assays, immunofluorescence and microscopy 
Raji cells were loaded or not with SEE at 1 μg/mL and labelled with 10 μM 7-amino-4-
chloromethyl coumarin (CMAC) for one hour at 37ºC. After two washes Raji cells were mixed 
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with J77 cells at a 1:1 cell ratio, briefly centrifuged, and gently resuspended. 50 µL of such 
mixture was plated on each poly-L-Lysine-coated coverslip and cells were allowed to interact 
for 20 minutes at 37ºC.  
 
For conjugates with primary cells, 100 µL of latex beads were coated with 900 µL of carbonate 
buffer containing 10 µg of anti-CD3ε (UCHT1) and 3 µg of anti-CD28 antibodies. As a negative 
control, beads were coated with 13 µg of isotype control (MOPC) in the same conditions. CD4 
T cells were mixed with coated beads at 1:1 ratio and allowed to interact for 20 minutes at 
37ºC.  When specified, cells were preincubated for 1 hour with PB3 (25 µM), which was 
maintained during the whole conjugation time.  
 
Both J77/Raji and CD4/bead conjugates were then fixed with 4% paraformaldehyde in PBS 
during 5 minutes at room temperature. When required, cells were then permeabilized with 
0,1% Triton X-100. Conjugates were blocked with 1:100 human IgG before staining with the 
indicated antibodies. When staining CD4/bead conjugates, additional blocking with mouse 
serum was performed. Blocking reagents and antibodies were diluted in TNB buffer. 
 
For live cell time-lapse confocal microscopy, J77 cells were attached to the bottom of LabTek 
chambered cover glasses coated with 20 µg/ml poly-L-Lysine. Then, Raji cells labelled with 
CMAC were added. Cells were imaged in DMEM without phenol red supplemented with 5% 
FCS and 25mM hepes buffer at 37ºC and 5% of CO2. 
 
Confocal microscopy was performed with a FV-1200 microscope (Olympus Deutschland GmbH, 
Germany). 405 nm (CMAC), 488 nm (GFP, Alexa488 and mCitrine), 559 nm (Cy3 and RFP) and 
594 nm (Alexa594 and mCherry) lines were used. The elapsed time used in time-lapse assays is 
indicated for each experiment. 
 
For total internal reflection fluorescence microscopy (TIRFM), cells were diluted in imaging 
medium (HBSS supplemented with 1% fetal bovine serum and 25 mM HEPES) and allowed to 
settle onto glass bottom dishes coated with ICAM-FC (10 µg/ml), anti-CD3ε (UCHT-1, 10 
µg/mL) and anti-CD28 (3 µg/ml). Cells were immediately visualized with an AM TIRF MC M 
system mounted on a DMI 6000B microscope coupled to an Andor-DU8285_VP-4094 camera 
and fitted with a HCX PL APO 100.0x1.46 OIL objective. Images were processed with the 
accompanying confocal software. The laser penetrance used was 150 or 200 nm for both laser 
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channels (488 and 561 nm), using the same objective angle. Synchronization was performed 
with the accompanying Leica software.  
 
Processing, analysis and quantification of fluorescence images were developed with FIJI free 
ware (NIH, USA). Polarization of molecules to the synapse was quantified using 
SynapseMeasures Plugin (153). 
 
2.8 Flow cytometry 
2.8.1 Intracellular staining 
For each staining, 0,3x106 cells were washed with PBS, fixed with PBS + 4% paraformaldehyde 
for 20 minutes at 4ºC, permeabilized with PBS + 1% FCS + 0,1% saponin for 15 minutes at RT 
and stained with primary antibodies for 30 minutes at 4ºC. When required, cells were washed 
and incubated with a secondary antibody for 30 minutes. After two washes, cells were 
resuspended in PBS + 1 mM EDTA and flow cytometry data were collected using a FacsCalibur 
flow cytometer.  
 
2.8.1 Extracellular staining 
For each staining, 0,1-0,2x106 cells were washed with PBS and stained with the indicated 
antibodies for 30 minutes at 4ºC. Cells were then washed twice with PBS, resuspended in PBS 
+ 1 mM EDTA and flow cytometry data were collected using a FacsCalibur flow cytometer. For 
analysing CD69 surface expression in J77/RAJI mixtures, CD19/CD69 double staining was 
performed and J77 cells were identified inside forward scatter/side scatter (FSC/SSC) cell gate 
by the negative staining for CD19 marker (Figure MM2). Flow cytometry data were analysed 
using the Flowjo software (Treestar, Inc.). 
 
 
Figure MM2. Gating strategy. The gates performed to analyze CD69 expression in J77 cells stimulated with RAJI 
cells are shown. A representative histogram of CD69 staining in the J77 gate is shown on the right side. 
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2.9 PCR from genomic DNA 
Genomic DNA from J77 cells was extracted with the IllustraTM DNA Extraction Kit BACC2. PCR 
reactions were performed with 200 μM of each deoxynucleotide triphosphate (dNTP), 400 nM 
of each primer, 0,5 units of Taq polymerase and 250 ng of genomic DNA. PCR products were 
run in a 1% agarose gel and purified using the QIAquick Gel Extraction Kit. Sequencing of 
purified products was performed in an ABI Prism 3730 DNA analyser using nested primers. 
 
2.10 Real- time quantitative PCR (qPCR) 
Total RNA was extracted using the Absolutely RNA Microprep Kit and the RNA integrity was 
assessed using the Agilent 2100 Bioanalyzer. 2 µg of RNA were used to synthesize cDNA with 
the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, USA). 
 
Expression profiles were obtained by qPCR implemented with TaqMan Low Density Arrays 
(TLDAs) in a 7900HT Fast Real-Time PCR System. Genes with CT values under 33 were 
considered to be non-expressed. Delta CT (DCT) was calculated by using as housekeeping gene 
the average of CT values obtained for the genes 18S and GNB2L1.  
 
When analyzing the expression profiles of naïve vs Th1 cells, consistent changes in the 
expression levels were considered significant when the difference in expression was equal to 
or higher than 1,5 CTs in the majority of donors analyzed and the p value of a paired T test was 
under 0.1. When analyzing expression changes during Th1 restimulation, consistent changes in 
the expression levels were considered significant when the difference in expression was equal 
to or higher than 1 CT in the majority of donors analyzed and the p value of a paired T test was 
under 0.1. 
 
Conventional qPCRs were performed using Taqman reagents. Reactions were run in 7900HT 
Fast Real-Time PCR system. Comparative analysis of the results obtained was done comparing 
the RQ values. RQ was calculated using the 2−ΔΔCT method (154), using GNB2L1 as 
housekeeping gene. 
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2.10 ELISA 
Supernatants of J77/Raji or CD4/beads co-cultures were collected and stored at -80ºC until 
analysis. IL-2 production was determined by ELISA assays using the BD OptEIATM ELISA set. 
Quantification was done in an ELx800 absorbance microplate reader. Absorbance values were 
interpolated in a standard curve using Excel software. 
 
2.11 Western Blot 
In order to analyze the integrity of plasmids used (Figure R6), transfected cells were lysed for 
30 min in ice-cold RIPA buffer and sonicated in a digital sonifier. 
 
In order to analyze phosphorylation of PLCγ and ERK1/2, stimulated cells were lysed for 30 min 
in ice-cold Western Blot (WB) lysis buffer. Cell lysates were centrifuged at 1000 g for 10 min at 
4ºC, and supernatants were collected for further procedure.  
 
For immunoprecipitation (IP), cells were lysed for 30 min in ice-cold IP lysis buffer. Cell lysates 
were then sonicated in a sonifier. Equilibrated GFP-Trap®_A beads were added to cell lysates 
and incubated for 2 hours at 4ºC with rotation. After two washes, Laemmli buffer was added 
and beads were boiled for 10 min at 95ºC to dissociate complexes. WB was performed with 
the supernatants.   
 
Cell lysates were mixed with 4x Laemmli buffer containing 20% β-mercaptoethanol. Samples 
were then boiled at 95°C for 5 minutes and proteins were separated by SDS-PAGE in 
acrylamide gels. Proteins were then transferred to an Immobilon-FL transfer membrane. After 
transference, membranes were blocked with either LICOR or BSA blocking buffer before O/N 
incubation with primary mouse or rabbit antibodies.  Fluorescently-labelled secondary 
antibodies IRDye 680 goat anti-Mouse and IRDye 800 goat anti-rabbit were used. In some 
experiments, HRP-conjugated goat anti-rabbit antibody and PierceTM ECL Plus Substrate were 
used.  Blots were scanned and fluorescence or quimioluminiscence were quantified with an 
Odyssey Infrared Imager. When needed, membranes were stripped using PVDF Stripping 
buffer from LICOR. 
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2.12 Data analysis and statistics 
Hitmap and dendrogram of expression data were generated using MATLAB software. 
Statistical analysis was implemented with PRISM 6 and Statgraphics Centurion XVII. When 
comparing three or more samples, one-way ANOVA followed by Bonferroni's multiple 
comparing test correction was used. When comparing two samples, Student T test was 
performed. Welch correction was applied when variances between samples were statistically 
different. Normalized values were analyzed by a one-sample T test. All tests were 
implemented with two tails unless otherwise stated in figure legends.  
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RESULTS 
1. Expression profile of PTPs associated to Th1 polarization 
 
The expression profile of NC PTPs had not been studied in human CD4 T cells upon 
differentiation to an effector phenotype and subsequent activation. In addition, the role of the 
majority of NC PTPs in T cell immune responses is unknown. Therefore, as a first attempt to 
understand their role in this process, we decided to study the changes in PTP expression 
during differentiation of naïve CD4 T cells into Th1 effector cells. We studied the expression of 
65 NC PTPs present in the human genome according to Alonso et al (87), and 14 classical PTPs. 
The latter were included due to their regulatory role in signaling downstream the TCR and 
cytokine receptors, or due to their association with autoimmune diseases (Table R1). The 
complete list of genes included in the study is shown in Table MM4.  
 
Table R1. Classical PTPs included in this study 
Phosphatase Substrate Function in T cells Autoimmunity Reference(s) 
PTPRA (RPTPα) SFK Regulation of TCR signalling Not reported (155) 
PTPRC (CD45) SFK and JAK 
family kinases 
Regulation of TCR and 
cytokine signalling 
MS, AH (156) 
PTPRJ (CD148) SFK Regulation of TCR signalling Not reported (157, 158) 
PTPRK (RPTPκ) STAT3 Regulation of CD4+ T cell 
development 
NK/T cell 
lymphoma 
(159, 160) 
 
PTPN1 (PTP1B) STAT6 Not reported Not reported (161) 
PTPN2 (TC-PTP) SFK, JAK1, JAK3 Regulation of TCR and 
cytokine signalling 
T1D, CD (162, 163) 
PTPN4 (PTP-MEG1) CD3ζ Regulation of TCR signalling Not reported (164) 
PTPN6 (SHP1) SFK, ITAMs, 
ZAP70, SLP-76 
Regulation of TCR signalling PS (165) 
PTPN7 (HePTP) ERK1/2, p38 Regulation of TCR signalling Not reported (166, 167) 
PTPN9  
(PTP-MEG2) 
NSF, STAT3 Regulation of cytokine 
secretion 
Not reported 
 
(168, 169) 
PTPN12 
 (PTP-PEST) 
Pyk2 Regulation of secondary T 
cell responses 
Not reported 
 
(170) 
PTPN13  
(PTP-BAS or PTP-BL) 
STAT4, STAT6 Regulation of cytokine 
signalling 
Not reported 
 
(171) 
PTPN18 (PTP20) HER2 Not reported Not reported (172) 
PTPN22 (LYP) ZAP70, LCK, FYN Regulation of TCR signalling T1D, RA, SLE (173, 174) 
Table R1. Classical PTPs included in this study. Classical PTPs, their known substrates, function in T cells, and role in 
autoimmune diseases are reported. SFK: Src family kinases, MS: Multiple sclerosis, AH: Autoimmune Hepatitis, T1D: 
Type I diabetes, CD: Crohn’s disease, PS:psoriasis, RA: Rheumatoid Arthritis, SLE: Systemic Lupus Erythematosus. 
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Human naïve CD4 T cells were isolated and polarized to Th1 conditions as detailed in materials 
and methods. Th1 polarization was assessed by induction of the Th1 master regulator 
transcription factor Tbet (Figure R1A). Production of IFNγ by Th1 cells in response to phorbol 
esters and Ionomycin treatment was also analyzed (Figure R1B). 
  
 
 
 
 
Expression of PTPs was analyzed in naïve and Th1 cells by using as housekeeping gene the 
average of the DCT values obtained from the genes 18s and GNB2L1. We found that the mRNA 
of all 14 classical PTPs and 52 out of 65 NCs was detectable in both the analyzed human naïve 
and Th1 cells. An agglomerative hierarchical tree (Figure R2) revealed clusters of PTPs, which 
shared not only the expression levels and profiles during Th1 polarization but also, in some 
cases, related functions (see section 1 of the Discussion). The PTPs significantly regulated 
during Th1 polarization are detailed in Table R2. 
 
 
Figure R1. Assessment of Th1 
polarization. A. Determination of the RQ 
of the transcription factors Tbet and 
GATA3 in naïve and Th1 cells. The average 
and the standard deviations of 3 donors 
are shown. B. Analysis of IFNγ production 
by in vitro-polarized Th1 cells before (Th1) 
and after (Th1-PI) restimulation with PMA 
and Iomoycin was analyzed by 
intracellular flow cytometry. The 
percentage of IFNγ producing cells (IFNγ+) 
is indicated. A representative experiment 
is shown. SSC, side scatter. 
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Figure R2. Expression profile of PTPs in naïve and Th1 cells. Agglomerative hierarchical tree of the gene expression 
patterns in naïve and Th1 cells. Numbers below the tree indicate the Euclidean distance among gene patterns. 
Hitmap represents the average DCT obtained for each gene in both conditions and 3 donors. The calibration bar is 
shown between 5 and 20 DCTs. Green and red squares point to clusters of upregulated and downregulated genes, 
respectively. Clusters of high, medium, and low expressed PTPs are indicated. Asterisks indicate those genes whose 
expression levels were considered to significantly change following the criterium stated in the main text. •, p≤0.1; *, 
p≤0.05; **, p≤0.01. 
 
 
1.1 Expression of classical PTPs 
The majority of classical PTPs analyzed (10 out of 14) were found inside the group of high 
expression, including PTPRA, PTPN22, PTPN2, PTPN12, PTPN4, PTPRJ, PTPN6, PTPN7, PTPN1 
and PTPRC. PTPRC, an important regulator of Lck activation (175), showed the highest 
expression levels of all PTPs included in this study. The remaining classical PTPs were found in 
the group of medium (PTPN9) or low (PTPRK, PTPN13 and PTPN18) expression. 
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Table R2. PTPs regulated during Th1 polarization. PTPs whose expression levels were regulated during Th1 polarization are 
shown. Changes in expression were determined as explained in materials and methods. Dots and asterisks represent the 
result of the paired T test of DCt values obtained for the comparison of naïve and Th1 cells in 3 donors. • p<0.1; * p≤0.05; ** 
p≤0.01. The absolute value of the average DCT change in the 3 donors is shown. DUSP13 and DUSP21 were considered as 
repressed genes since their expression was detectable only in naïve but not in Th1 cells. MTMR11 and CDC25C were 
considered as induced genes since their expression was detectable in Th1 but not in naïve cells. 
Table R2. PTPs regulated during Th1 polarization 
Group Gene  Regulation 
during Th1 
polarization 
Average DCT 
change/p 
value 
Substrate 
 
Classical 
 
 
 
 
PTPRJ  Upregulation 2.02/* SFK 
PTPN6  Upregulation 2.08/* SFK, ITAMs, ZAP70, 
SLP-76, Vav1 
PTPN7  Upregulation 1.54/* ERK1/2, p38 
PTPN9  Upregulation 2.45/* NSF 
PTPN13  Upregulation 2.40/* STAT4, STAT6 
PTPN18  Upregulation 1.9/• HER2 
MKPs and 
Atypical DSPs 
 
 
 
 
 
 
DUSP1  Downregulation 3.07/** p38, JNK, ERK 
DUSP7 Upregulation 2.10/• ERK 
DUSP8 Downregulation 4.55/* JNK,p38 
DUSP13 Repression --- JNK,p38 
DUSP16 Downregulation 1.20/• JNK,p38 
MK-STYX Upregulation 1.19/• Catalytically inactive 
DUSP21 Repression --- Unknown 
DUSP22 Upregulation 2.10/* JNK,ERK2, Lck 
DUSP23 Upregulation 1.57/** p38, JNK 
Myotubularins 
and PTEN DSPs 
 
 
MTMR1 Upregulation 1.43/** PI(3)P, PI(3,5)P2 
MTMR2 Upregulation 2.61/* PI(3)P, PI(3,5)P2 
MTMR11 Induction --- Catalytically inactive 
TPIP Downregulation 1.96/• PIP 
Cell cycle 
regulators  
 
CDKN3 Upregulation 5.81/* CDK2 
CDC25A Upregulation 6.80/* CDKs 
CDC25B Upregulation 2.45/* CDKs 
CDC25C Induction --- CDKs 
Class III Cys-
based PTPs 
SSH2 Downregulation 1.68/* Cofilin 
SSH3 Upregulation 2.63/** Cofilin 
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1.2 Expression of NC PTPs 
We did not detect mRNA of the MKP DUSP9, the atypical DSPs DUSP15, DUSP26, and DUSP27, 
the tensin homolog TPTE, the myotubularin MTMR7 and the Asp-based PTPs EYA1, EYA2, and 
EYA4 in either naïve or Th1 cells. Non expressed MKPs in our study matched previous data in 
mice (176). In contrast, the reported expression of the Eya1, Eya2, and Eya3 mouse orthologs 
(176) suggests a different requirement of this group of PTPs in mice and humans. The same 
might apply for the myotubularin MTMR7, which seems to have a regulatory role in Th 
polarization in mice (177). 
 
22 NC were found in the group of highly expressed PTPs (Figure R2). Substantial changes in 
expression levels associated with Th1 polarization were found in genes coding for regulators of 
the phosphorylation state of phosphoinositides (TPIP and MTMs), the MAPK signalling module 
(MKPs), the actin cytoskeleton (SSHs), and the cell cycle (CDC25s and CDKN3) (Table R2). The 
changes in the expression of these genes will be further discussed in the section 1 of the 
discussion. Here we will only briefly outline the level of expression (high, medium or low, see 
Figure R2) of the groups of PTPs.  
 
Among the ten out of eleven classical MKPs whose expression was detected, five (DUSP1, 
DUSP2, DUSP4, DUSP7, and DUSP16) were found in the group of highly expressed PTPs, and 
five (DUSP5, DUSP6, DUSP8, DUSP10 and STYXL1) were found inside the group of medium 
expressed PTPs.  
 
Among the DSPs, only STYX and DUSP11 were found in the group of higly expressed PTPs, 
while DUSP3, DUSP12, DUSP14, DUSP22, DUSP23 and RNGTT where in the group of medium 
expression. The DSPs with low expression were DUSP18, DUSP19 and EPM2A. 
 
Among the tensin homologs only PTEN was highly expressed particularly in Th1 cells. The other 
components of the PTEN family, TPIP, TNS1 and TENC1 shared a cluster of very low expression. 
 
Regarding MTMs, 9 out of 16 (MTM1, MTMR1, MTMR3, MTMR4, MTMR6, MTMR10, MTMR12, 
MTMR14 and SBF1, which encodes for MTMR5) were found in the group of highly expressed 
PTPs, suggesting that these enzymes are important regulators of phosphoinositide levels in T 
cells. The other MTMs whose expression was detected were in the group of medium 
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expression (MTMR2, MTMR8, MTMR9, FAN1, which encodes for MTMR15, and SBF2, which 
encodes for MTMR13).   
 
Among cell cycle regulators, CDC14A and CDC25B were found in the group of highly expressed 
PTPs. CDC25A, CDKN3 and PTPDC1 were in the group of medium expressed genes. 
 
The cytoskeleton regulators SSH1, SSH2 and SSH3 were found in the medium, high, and low 
expression groups, respectively. 
 
Among the PRL phosphatases, PTP4A1 and PTP4A2 were highly expressed, while PTP4A3 was 
in the group of medium expression. 
 
 
2. Expression of NC PTPs during stimulation of Th1 cells 
 
The finding that the expression levels of several NC PTPs were regulated during Th1 
polarization prompted us to further investigate their expression during the effector functions 
of Th1 cells at inflammatory sites. We used PMA and Ionomycin (PI) stimulation for 4 hours to 
mimic strong stimuli that effector cells receive upon extravasation to sites of inflammation. 
PMA is a DAG analog that induces PKC and RasGRP activation (178, 179), while Ionomycin is an 
ionophore that trigguers elevation of intracellular Calcium levels (180).  
  
While the cell cycle regulators (CDC14s and CDC25s) were in general downregulated during 
Th1 stimulation (Figure R3B), all the MAPK regulators (MKPs and atypical DSPs) that showed 
significant changes in their expression levels upon Th1 stimulation were upregulated (Figure 
R3A). Consistent with our data, the ERK-specific DUSP5 has been shown to be upregulated in 
human T cells in response to IL-2 stimulation (181), and it has been reported that both DUSP5 
and DUSP6 are upregulated in MCF7 cells upon PMA treatment (182). DUSP8 expression has 
also been shown to be induced in K562 cells by PMA (183).  
 
Among phosphoinositide phosphatases (PTENs and MTMRs) only MTMR3 was significantly 
downregulated, while MTMR2 and MTMR11 were upregulated by PI treatment (Figure R3C). 
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The tensin homolog TPIP was repressed with Th1 stimulation and could not be included in 
Figure R3C.  
 
Two out of three members of the PRL family were significantly regulated during Th1 
stimulation (Figure R3E). Interestingly, while PTP4A1 was upregulated, PTP4A2 was 
downregulated, suggesting that despite their high homology, these proteins might play distinct 
roles in Th1 cell responses. This finding, together with the reported high expression of PTP4A1 
and PTP4A2 in T cell areas of the lymph node (127) and the proposed role of PRLs as regulators 
of the actin cytoskeleton (116, 147, 148) prompted us to further analyze the expression of 
PRLs in CD4 T cells, and their role in IS assembly and T cell activation.  
 
 
 
Figure R3. Expression changes of NC PTPs upon Th1 stimulation. In vitro polarized Th1 cells were stimulated with 
PMA an Iomomycin for four hours and gene expression was measured. The graphs represent the average of the 
change in DCT between Th1 and restimulated Th1 cells for the main functional groups of PTPs (A to E). Genes 
upregulated and downregulated are labelled in green and red, respectively. Asterisks indicate those genes whose 
expression levels were considered to significantly change following the criterium stated in materials and methods. 
The mean ± SD of three donors is shown. • p≤0.1; * p≤0.05; ** p≤0.01. 
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3. PRLs participate in T cell activation 
 
To further analyze the regulation of PRLs expression during T cell stimulation, we used both in 
vitro generated Th1 and peripheral blood CD4 T cells. As shown in Figure R4A, PTP4A2 was the 
most abundant PRL in both cells, followed by PTP4A1 and PTP4A3, successively. In addition, 
the expression of PTP4A1 and PTP4A2 was similar to other PTPs known to regulate T cell 
responses (88). Next, we performed a time-course experiment stimulating with PMA and 
Iomomycin both Th1 and peripheral blood CD4 T cells (Figure R4B and C). PKC/RasGRP 
stimulation and intracellular rise of Ca2+ obtained by this treatment caused an up-regulation of 
PTP4A1 concomitant to a quick down-modulation of PTP4A2. While Th1 effector cells showed 
a higher and more sustained rise of PTP4A1 (Figure R4C), a lower transient peak at 30 minutes 
was observed in ex vivo analyzed peripheral blood CD4 T cells (Figure R4B). Interestingly, Th1 
cells induced higher levels of both PTP4A1 and CD69 (Figure R4D). No consistent changes were 
observed for PTP4A3 (data not shown).  
 
 
Figure R4. Expression of PRLs in CD4 T cells. A. Gene expression of PRLs and other PTPs in peripheral blood CD4 T 
cells and in vitro polarized Th1 cells from 3 healthy donors was analyzed by qPCR. The mean value of DCT ± SD for 
each gene is shown. The significance of a one-way ANOVA test in CD4/Th1 cells is indicated with asterisks. n.s. not 
significant. B and C. Expression of PTP4A1 and PTP4A2 mRNA in peripheral blood CD4 T cells (B) and Th1 cells (C) 
during stimulation with PMA and Ionomycin for the indicated times. Asterisks indicate comparison to t=0 using a 
one sample T test. Hashes indicate comparisons between PTP4A1 and PTP4A2 using a paired T test. D. Induction of 
CD69 mRNA during stimulation. (B to D) The mean value of RQ ± SD from four different donors is shown. (A to C) * 
and # p≤0.05; ## and ** p≤0.01; *** p≤0.001. 
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Expression data indicated that T cell stimulation leading to PKC/RasGRP activation and Ca2+ 
elevation increased the relative amount of PRL-1 compared with PRL-2. Hence, we 
hypothesized that these molecules could have a role during T cell activation. To test this 
hypothesis, we treated peripheral blood CD4 T cell with Thienopyridone (TP), a selective 
inhibitor of the enzymatic activity of this group of DSPs (137), before and during T cell 
stimulation with anti-CD3ε and anti-CD28. TP treatment decreased the induction of the 
activation marker CD69 (184) and the secretion of IL-2 (Figure R5). No clear effects were found 
when cells were treated with Analog 3 (A3), a less specific drug that also inhibits classical PTPs 
(185), such as the negative regulator of TCR signaling TC-PTP (162). Although the effect of TP 
was not as patent as the effect of the MEK inhibitor U0126, these data suggested that the 
enzymatic activity of PRLs was required for the optimal activation of human CD4 T cells. 
 
 
Figure R5. Contribution of catalytic activity of PRLs to T cell activation. Effect of the MEK1 inhibitor U0126, Analog 
3 and thienopyridone on CD69 induction (A) and IL-2 secretion (B) in CD4 T cells in response to T cell stimulation 
with anti-CD3/anti-CD28 coated beads. Results were normalized to control (DMSO) and the mean ± SD of four 
experiments is shown. Samples were compared with the control (DMSO) by a one-sample T test. * p≤0.05;  ** 
p≤0.01; *** p≤0.001. 
 
4. Recruitment of PRL-1 to the IS  
 
The obtained expression data, together with the effect of TP on T cell stimulation, suggested 
that PRLs might play a role in T cell activation. Given that PTP4A1 was the only member of the 
PRL family that was transiently upregulated during PI treatment, we decided to study its 
distribution during IS formation. Distribution of endogenous PRL-1 at the T cell side of the IS 
was imaged in IS-like structures formed by peripheral blood CD4 T cells of healthy donors and 
latex beads coated with anti-CD3ε and anti-CD28 antibodies as described in materials and 
methods. PRL-1 staining was performed with a mouse monoclonal antibody kindly provided by 
Dr. Qi Zeng (Institute of Molecular and Cell Biology, Singapore) that showed specificity to PRL-1 
with respect to PRL-2 and PRL-3, as assessed by intracellular staining of chimeric proteins 
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(Figure R6A, α-PRL-1 panels). By contrast, a commercial antibody recognized both PRL-1 and 
PRL-2 (Figure R6A and R6C, α-PRL-1/2 panels). 
 
Co-staining with α-tubulin revealed that PRL-1 accumulated at the IS-like structures in cells 
showing or not polarization of the MTOC, while it was not recruited to interfaces established 
with non-stimulating control beads (Figure R7A). Interestingly, two pools of PRL-1 were 
observed; one around the MTOC and another accumulated at the IS (Figure R7B). PRL-1 
accumulation at T cell membranes contacting latex beads correlated with the recruitment of 
CD3ζ (Fig. R7C), indicating that PRL-1 polarization is associated to the activation process. 
 
 
 
Figure R6. Assessment of α-PRL-1 antibody specificity and plasmid integrity. A. Intracellular staining of 
overexpressed chimeric proteins in Jurkat cells with a monoclonal antibody α-PRL-1 provided by Dr. Qi Zeng, and a 
commercial α-PRL-1/2 antibody. Fluorescence of the overexpressed protein is displayed in the X axis; fluorescence 
of the intracellular staining is displayed in the Y axis. B. Immunofluorescence of a Jurkat cell transfected with the 
mCit-PRL-1 chimeric protein stained with α-PRL-1 antibody. C. WB of Jurkat cells transfected with mCit-PRL-1, mCit-
PRL-2, GFP-PRL-1, GFP-PRL-1-ΔCAAX or GFP alone, probed with α-GFP or α-PRL1/2 antibodies. TL, Transmitted light; 
MWM, Molecular weight marker. 
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Figure R7. Distribution of endogenous PRL-1 at the IS. A. Representative immunofluorescences of CD4 T cells 
interacting with microspheres coated with anti-CD3ε and anti-CD28 antibodies (IS-like) or IgG1 as negative control 
for stimulation. The right panel represents the quantification of PRL-1 redistribution to the IS in relation to MTOC 
polarization. The numbers represent the mean for each group. Groups were compared by a one-way ANOVA. * 
p≤0.05, ** p≤0.01. B. Representative immunofluorescence of CD4 T cells interacting (IS-like) or not (Unstimulated 
cell) with microspheres coated with anti-CD3ε and anti-CD28 antibodies. Right panels represent profiles of the 
fluorescence intensity in the green and the red channel along the line drawn on images. Numbers indicate the 
correspondence between the cell and the profile. C. Representative images of CD4 T cells interacting with 
microspheres coated with anti-CD3ε and anti-CD28 antibodies. Examples of IS-like interactions showing or not 
polarization of PRL-1 and CD3ζ are shown. The right panel represents the correlation of PRL-1 and CD3ζ polarization 
to the IS. The p-value of the Pearson coefficient is shown. (A to C) Calibration bar is shown in pseudocolored images. 
Scale bars 5 μm. Dots represent individual conjugates from two independent experiments. 
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To study the distribution of PRL-1 in a system with antigenic stimulation, we used the J77 T cell 
line, which can be stimulated by RAJI cells presenting SEE. To directly visualize endogenous 
PRL-1 in J77 cells with no antibody staining, we edited the genome of J77 cells. By using 
Crispr/Cas9 technology, we inserted a GFP cassette in the genome of J77 cells right before the 
coding sequence of the PRL-1 gene (see materials and methods section 2.4). As a result, we 
obtained a cell line expressing endogenous PRL-1 coupled to the GFP. As shown in Figure R8A, 
edited J77 cells (GFP+) were enriched by cell sorting. Proper insertion of the GFP coding 
sequence in genomic DNA of edited cells was assessed by PCR (Figure R8B) and integrity of the 
endogenous chimeric protein, as well as the absence of free GFP was confirmed by WB (Figure 
R8C).  
 
 
Figure R8. Caracterization of the GFP-PRL-1 J77 KI cell line. A. Dot plots showing the percentage of cells with the 
GFP cassette inserted in the genome (edited cells) before and after enrichment by cell sorting. Histogram on the 
right represents fluorescence of control J77 and KI cells before and after sorting. B. Insertion of GFP in the PTP4A1 
gene was assessed by PCR. PCRs were designed as shown in the scheme to amplify a fragment corresponding to the 
end of 5'HA and the beginning of the GFP coding sequence (5'HA-GFP) and a fragment corresponding to the end of 
GFP and the beginning of the 3'HA (GFP-3'HA). Arrows represent the primers used. The start codon of the PRL-1 
coding sequence is shown. PCRs were run in agarose gels and visualized with ethidium bromide staining. 
Arrowheads indicate the specific band. C. Immunoprecipitation was performed with GFP traps to pull down the 
GFP-PRL-1 protein, followed by WB with the indicated antibodies. C, Control; KDa, KiloDalton. 
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We also transfected J77 cells with plasmids coding for chimeric GFP-PRL-1 or GFP alone to 
compare the result of overexpression and genomic edition. The overexpressed chimeric 
protein conserved the epitope recognized by the α-PRL-1 antibody and had the expected 
molecular weight (Figure R6). In unstimulated cells, overexpressed (o/e) GFP-PRL-1 cells 
showed a distribution consistent with the previous endogenous PRL-1 staining, with an 
intracellular pool of GFP-PRL-1 distributed around the MTOC (Figure R9A). Next, we examined 
GFP-PRL-1 recruitment to the mature IS formed between J77 and RAJI cells presenting SEE. The 
low expression levels of endogenous PRL-1 in J77 cells difficulted the visualization of 
endogenous GFP-PRL-1 when fixed cells were permeabilized prior to tubulin staining. Hence, KI 
cells were stained for surface CD3ε. Both KI and o/e GFP-PRL-1, but not GFP alone, polarized to 
the zone of contact (Figure R9B). Interestingly, KI GFP-PRL-1 showed polarization rates more 
similar to the endogenous PRL-1 (mean 1,23 and 1,48, respectively, Figures R7A and R9B) than 
the o/e GFP-PRL-1 (mean 2,27, Figure R9B). These results indicated that although both systems 
enabled us to evaluate the polarization to the IS, genomic edition reproduced more accurately 
the behaviour of the endogenous molecule.  
 
 
Figure R9. Distribution of GFP-PRL-1 in J77 T cells. A. Representative immunofluorescence of a J77 cell 
overexpressing GFP-PRL-1 and stained for α-tubulin. The right panel represents the profile of the fluorescence 
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intensitiy in the green and the red channels along the line drawn in the merged image. B. Representative 
immunofluorescences of cell conjugates formed by J77 KI cells (KI GFP-PRL-1) or J77 cells overexpressing GFP-PRL-1 
(o/e GFP-PRL-1) or GFP alone (GFP) and conjugated with SEE-pulsed RAJI cells labeled with CMAC (blue). The right 
panel represents the quantification of the distribution of GFP-PRL-1 to the IS. The mean of each group is indicated 
on the graph. Dots represent individual conjugates. Asterisks indicate the p-value of a one-way ANOVA test. * 
p≤0.05, *** p≤0.001. Scale bars 5 μm. 
 
The accumulation of endogenous PRL-1 at the IS in which the MTOC was not completely 
polarized (Figure R7A) suggested that PRL-1 was delivered to the contact site before the IS 
maturation. To further prove this idea the polarization of the GFP-PRL-1 fusion protein was 
tracked in live cells from the initial scanning of the APC until the complete assembly and 
maturation of the IS. The low expression levels of endogenous PRL-1 in J77 cells made 
necessary to increase the laser voltage to visualize GRP-PRL-1 in KI cells, leading to fast 
bleaching of the chromophore. Hence, time-lapse experiments had to be performed with o/e 
GFP-PRL-1. Time-lapse confocal microscopy revealed a fast and transient accumulation of PRL-
1 at membrane protrusions during initial stages of the APC scanning and a later delivery at the 
mature IS in the pericentriolar endosomal compartment (Figure R10A and B, white arrows and 
yellow arrowheads for initial contacts and intracellular compartment, respectively, and Movies 
1 and 2). PRL-1 colocalized with CD3ζ at dynamic membrane protrusions scanning the APC 
surface during the interaction (Figure R10B, white arrows). Plasma membrane targeting and 
delivery of PRL-1 to the IS was dependent on the CAAX motif, as shown by overexpression of 
the mutant GFP-PRL-1-ΔCAAX, which lacks this sequence (Figure R11). 
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Figure R10. Dynamic distribution of GFP-PRL-1 to the IS. Formation of conjugates between J77 cells overexpressing 
GFP-PRL-1 (green) and CD3ζ-mCherry (red) and SEE-pulsed RAJI cells (labelled in blue) was imaged by time-lapse 
confocal microscopy. A. Frames of the experiment in Movie 1 are shown. The distribution of GFP-PRL-1 is shown in 
the pseudocolor (lower panels) and in the merged (upper panels) images. White arrows indicate transient 
accumulation of GFP-PRL1 at scanning membranes. Yellow arrowheads indicate the pericentriolar location of GFP-
PRL-1. B. An early and a late frame of the experiment in Movie 2 are shown. The distribution of GFP-PRL-1 is shown 
in the pseudocolor and merged images. White arrows indicate the colocalization of GFP-PRL1 and CD3ζ-mCherry at 
scanning membranes. Yellow arrowhead indicates the intracellular compartment containing GFP-PRL-1. 
Colocalization is shown in a pixel map (pm) obtained at the interaction zone. White pixels indicate colocalization 
sites. Scatter plots of green and red channels are shown. Numbers indicate the Manders coefficient (MC). Scale bars 
5 μm. Time in seconds (s) is indicated for each image. 
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Figure R11. Distribution of GFP-PRL-1-ΔCAAX in J77 cells. Images from time-lapse experiments performed with J77 
cells expressing CD3ζ-mCherry and either GFP-PRL-1 (A) or GFP-PRL-1-ΔCAAX (B) interacting with SEE-pulsed RAJI 
cells labeled with CMAC (blue). White arrows indicate CD3ζ-mCherry vesicles containing GFP-PRL-1 but not GFP-
PRL-1-ΔCAAX. Scale bars 10 μm. Time in seconds (s) is indicated for each image. 
 
Distribution of PRL-1 at the established IS was further studied by confocal microscopy in fixed 
samples (Figure R12). Overexpressed mCit-PRL-1 clearly colocalized with LFA-1 at the IS. Partial 
colocalization with surface CD3ε was also observed in more restricted areas. As a negative 
control, we analyzed colocalization of YFP alone with CD3ε. 
  
To further analyze the colocalization of PRL-1 with CD3ζ we used TIRFM, which allows for 
higher spatial and temporal resolution. We imaged IS-like structures formed by J77 cells upon 
stimulation on glasses covered with anti-CD3ε, anti-CD28 and ICAM-1. During early adhesion of 
T cells to these activating surfaces, GFP-PRL-1 clearly localized in clusters enriched in CD3ζ-
mCherry (Figure R13A and Movie 3). These results suggested that PRL-1 could be included in 
signaling aggregates organized during initial T cell activation, as described for other molecules 
such as ZAP-70 (186). In already established IS, we observed transient copresence of GFP-PRL-1 
and CD3ζ-mCherry at dynamic peripheral sites and central CD3ζ-containing vesicles (Figure 
R13B, see profile and arrows in magnified areas, and Movie 4) as well as comigration of both 
molecules towards a more internal area of the interaction (Figure R13C, see kymograph, and 
Movie 5).  
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Figure R12. Colocalization of GFP-PRL-1 with LFA-1 and CD3ε at the IS. Upper images: immunofluorescence of cell 
conjugates formed by J77 cells overexpressing mCit-PRL-1 and SEE-pulsed RAJI cells labeled with CMAC (blue).  Co-
localization is shown in a pixel map (pm) obtained at the interaction zone. White pixels indicate colocalization sites. 
Scatter plots of green and red channels are shown. Numbers indicate the Manders coefficient (MC). A 3D 
reconstruction of the IS where co-localization was analyzed is shown. Scale bars 10 μm. Lower graphs: 
quantification of the colocalization by Manders and Pearson coefficients (MC and R, respectively). Dots represent 
individual cell conjugates from at least two experiments. Asterisks represent the p-values of unpaired T tests. ** 
p≤0.01, ***P≤0.001.  
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Figure R13. TIRFM imaging of GRP-PRL-1 and CD3ζ-mCherry at the IS. Images from TIRFM experiments performed 
with J77 cells expressing GFP-PRL-1 and CD3ζ-mCherry plated on glass bottom dishes coated with ICAM-Fc, anti-
CD3ε and anti-CD28 antibodies. A. Time frame of the experiment in Movie 3. B. Merged image of a time frame of 
the experiment in Movie 4. Lower graph represents the profile of the fluorescence intensity of the green and red 
channels on the line that would cross the numbered sites in the upper image. A magnified area of the region 
defined by a square is shown at different time points. White arrows indicate a CD3ζ-mCherry-containing vesicle to 
which GFP-PRL-1 arrives. Lower graphs represent the profile of the fluorescence intensity of the green and red 
channels on the line that would cross the vesicle. C. Time frame of the experiment in Movie 5. The lower panel 
shows the kymograph obtained with the arrow drawn in the image. (A to C) Time in minutes:seconds is indicated on 
each image. Penetration depth: A and B, 150 nm. C, 200 nm. 
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5. PRL-1 contributes to T cell activation 
 
 
The upregulated expression of PRL-1 upon T cell activation, the delivery to the IS and the 
colocalization with CD3 suggested that PRL-1 might regulate T cell activation. To address this 
possibility, we decided to investigate the effect of PRL-1 overexpression and PRL-1 inhibition 
on the induction of the activation marker CD69 and the production of IL-2. Initially, we 
performed PRL-1 overexpression (gain-of-function approach, GOF) in J77 cells and inhibition of 
PRL-1 catalytic activity (loss-of-function approach, LOF) in peripheral blood CD4 T cells (Figure 
R14A and B).  J77 cells transfected with the plasmid coding for mCit-PRL-1 or YFP alone were 
cultured for 16h with Raji B cells loaded or not with SEE. Then, CD69 surface expression was 
analyzed by flow cytometry and IL-2 secretion by ELISA. Both CD69 induction and IL-2 secretion 
were increased in cells overexpressing the mCit-PRL-1 chimera compared with cells expressing 
YFP alone (Figure R14A). Consistently, pharmacological inhibition of the catalytic activity of 
PRL-1 by the specific inhibitor Procyanidin B3 (PB3) (187) decreased the amount of IL-2 
secreted by peripheral blood CD4 T cells stimulated for 6 hours with beads coated with anti-
CD3ε and anti-CD28 monoclonal antibodies (Figure R14B, right panel), although no significant 
effect was detected on CD69 induction (Figure R14B, left panel). This discrepancy between J77 
and CD4 T cells prompted us to test whether PRL-1 overexpression had any effect on CD69 
induction in peripheral CD4 T cells. As shown in the graph of Figure R14C, cells expressing 
increasing amounts of mCit-PRL-1 expressed increasing amounts of CD69 (see gates on the left 
dot plot and grey series on the graph). By contrast, cells expressing increasing amounts of YFP 
(see gates on the right dot plot and white series on the graph) showed no difference in CD69 
induction. This result suggested that PRL-1 enhanced CD69 expression in a dose-dependent 
manner. Importantly, negative cells of both transfections (see the Negative cells gate in each 
dot plot, and the first point of the graph for each series) induced equal amounts of CD69, 
indicating that the same activating stimulus was applied to both conditions.  
 
Altogether, the results of GOF and LOF experiments suggested that PRL-1 contributes to T cell 
activation by a mechanism involving its catalytic activity. To further investigate this 
mechanism, we decided to address whether PRL-1 was regulating T cell activation through the 
regulation of the actin cytoskeleton reported in other cell types (116, 147, 148).  
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Figure R14. Regulation of T cell activation by PRL-1. CD69 expression was analyzed by flow cytometry and IL-2 
production by ELISA. A. CD69 expression and IL-2 secretion in J77 cells overexpressing mCit-PRL-1 or YFP alone and 
stimulated with RAJI cells pulsed with the indicated concentrations of SEE. The means ± SD of three (SEE 0 and 0.5) 
or two (SEE 0.25 and 1) experiments are shown. Asterisks represent the p-value of a one-tailed paired T-test. B. 
CD69 expression and IL-2 secretion in CD4 T cells stimulated with anti-CD3ε/anti-CD28 coated beads in presence of 
different concentrations of PB3. Results were normalized to control (PB3 0 μM). The means ± SD of three donors are 
shown. A and B. Asterisks represent the p-value of a one-tailed one sample T test. * p≤0.05. C. Dot plot showing 
CD69 expression in CD4 T cells overexpressing mCit-PRL-1 of YFP. The mean fluorescence intensity (MFI) of both 
channels in each region drawn on the dot plot is represented in the graph on the right. A representative experiment 
out of three is shown. MFI, mean fluorescence intensity. 
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6. PRL-1 regulates actin dynamics and PLCγ1 at the IS 
 
 
To investigate whether PRL-1 was regulating actin rearrangements at the IS, we imaged actin 
dynamics during IS formation using TIRFM. Initially, we tracked the formation of F-actin by 
using the LifeAct-RFP probe. An early, transient enrichment of GFP-PRL-1 preceded actin 
polymerization at contact sites (Figure R15A and Movie 6), suggesting that PRL-1 could 
participate in this process. Hence, we did GOF and LOF experiments to test this hypothesis.  
 
For GOF experiments, J77 cells were co-transfected with a plasmid expressing mCherry-β-actin 
and either the plasmid expressing GFP-PRL-1 or GFP alone. This model enabled us to observe 
the formation of the dSMAC/lamellipodium, which contains the retrograde flow of actin and 
surrounds a wide central area cleared of actin (15, 186). While cells overexpressing the GFP 
alone spread normally and showed a typical formation of a dSMAC, cells overexpressing GFP-
PRL-1 showed a reduced area of contact and a wider dSMAC surrounding smaller central areas 
with low actin density (Figure R15B). These experiments suggested a regulatory role of PRL-1 in 
actin dynamics during IS assembly.   
 
We further studied whether the catalytic activity of PRL-1 regulated F-actin dynamics during T 
cell activation by doing LOF experiments. Cells were treated with the inhibitor PB3 as 
described in materials and methods and allowed to interact with latex beads coated with anti-
CD3 and anti-CD28 antibodies as in Figure R7. Polymerization of F-actin at the IS was 
significantly reduced in cells treated with the inhibitor when compared with cells exposed to 
the vehicle as control (Figure R15C).  
 
These data indicated that the catalytic activity of PRL-1 regulates actin dynamics during the 
assembly of the IS. Given that actin polymerization at the IS is required for sustained PLCγ1 
activation (15), we decided to analyze PLCγ1 phosphorylation when PRL-1 was overexpressed 
or inhibited as before. We also analyzed ERK1/2 phosphorylation levels, since the PRLs have 
been shown to induce ERK1/2 activation in cancer cells (139). As shown in Figure R16A, GFP-
PRL-1 overexpression increased the activation of PLCγ1, while pharmacological inhibition of 
PRL-1 in peripheral blood CD4 T cells reduced it. No differences were detected in ERK 
phosphorylation (Figure R16B) when overexpressing PRL-1 or inhibiting its catalytic activity. 
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Figure R15. Regulation of actin dynamcs at the IS by PRL-1. A and B. Images from TIRFM experiments performed 
with J77 cells plated on glass bottom dishes coated with ICAM-FC, anti-CD3ε and anti-CD28 antibodies.. A. Images 
from three time frames of the experiment in Movie 6. Time in minutes:seconds is shown. The panel on the right 
shows the kymograph obtained with the line drawn on the merged image. Scale bar 10 μm. B. Representative time 
frames of two TIRFM experiments performed with cells overexpressing mCherry-β-actin (signal shown in 
pseudocolor) and GFP-PRL-1 or GFP alone (signal not shown). Kymographs were obtained with lines shown in the 
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frame. Scale bars 5 μm. Lower graphs represent total area and ratio of central to total area of contacts like the ones 
shown in the upper images. Each dot represents a single cell. C. Immunofluorescence of IS-like structures as in 
Figure R7. Cells were incubated in presence of PB3 (25 μM) or DMSO as control. Scale bars 5 μm. Graph on the right 
represents quantification of the actin accumulation at the IS interface. Dots in the graph represent individual 
cell/bead conjugates from four different donors. Asterisks represent the p-value of unpaired T-tests. * p≤0.05, *** 
p≤0.001. 
 
 
 
 
Figure R16. Regulation of early signalling downstream the TCR by PRL-1.  Left panel, J77 cells overexpressing GFP-
PRL-1 or GFP alone were stimulated with SEE-pulsed RAJI cells for the indicated times. Right panels, peripheral 
blood CD4 T cells were stimulated with ImmunoCult™ Human CD3/CD28 T Cell Activator for the indicated times in 
presence of PB3 (25 µM) or DMSO (control). A. Phosphorylated (pPLCγ1) and total PLCγ1 were analyzed by WB in 
J77 (left panel) and CD4 (right panel) cells. B. Phosphorylated (pERK1/2) and total ERK1/2 were analyzed by WB in 
J77 (left panel) and CD4 (right panel) cells. Graphs under the gels represent the mean ± SD of phosphorylated signal 
normalized to the total protein from three independent experiments. Samples at each time were compared by a 
paired T-test. Asterisks represent the p-value of the used tests. * p≤0.05. 
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Movie legends 
 
Movie 1 and Movie 2. Dynamic distribution of GFP-PRL-1 at the IS. Time-lapse confocal microscopy experiments of 
J77 cells overexpressing CD3ζ-mCherry (red) and GFP-PRL-1 (green) interacting with a SEE-pulsed RAJI cell (blue). In 
Movie 1 separated channels as well as merged and transmission light images are shown. In Movie 2 merged and 
transmission light images are shown. Time in seconds (sec) is indicated. Elapsed time 5 seconds in Movie 1 and 10 
seconds in Movie 2. Scale bars 10 μm. 
 
Movie 3. Colocalization of GFP-PRL-1 and CD3ζ-mCherry during early adhesion of T cells to activating surfaces. 
Time-lapse TIRFM experiment showing a J77 cell overexpressing with CD3ζ-mCherry (red) and GFP-PRL-1 (green). 
Green (left, displayed as pseudolocor) and red (middle) channels as well as the merged image (right) are shown. 
Time (minutes:seconds) is indicated on the pseudocolored image and scale bar (10 μm) on the merged image. 
Elapsed time 1 second. 
 
Movie 4 and Movie 5. Dynamic colocalization of GFP-PRL-1 and CD3ζ-mCherry at the IS. Time-lapse TIRFM 
experiments of J77 cells overexpressing CD3ζ-mCherry (red) and GFP-PRL-1 (green). Red (left) and green (middle) 
channels as well as the merged image (right) are shown. Time (minutes:seconds) and scale bar are indicated on the 
merged image. Elapsed time 1 second. 
 
Movie 6. Enrichment of GFP-PRL-1 at sites of actin polymerization during early adhesion of T cells to activating 
surfaces. Time-lapse TIRFM experiment showing a J77 cell overexpressing GFP-PRL-1 (green) and LifeAct–RFP (red). 
Green (left) and red (middle) channels as well as the merged image (right) are shown. Time minutes:seconds and 
scale bar (10 μm) are indicated. Elapsed time 1 second. 
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DISCUSSION 
 
1. Expression profile of NC PTPs during Th1 differentiation and 
restimulation 
 
PTPs are key regulators of signaling pathways involved in almost every cellular process. More 
than a hundred genes coding for PTPs have been identified in the human genome (87). 
Although it is known that T cells express a high number of these enzymes (88), whether they 
play a role in T cell responses is unknown for the majority of them, especially for NC PTPs. This 
work aimed to identify NC PTPs that might be potential regulators of T cell activation or 
differentiation. As an initial approach, we performed expression studies in naïve, Th1 and 
restimulated Th1 cells.  
 
The systematic analysis performed in this study reveals that several genes coding for PTPs are 
regulated during Th1 polarization and stimulation of effector cells. Regarding Th1 polarization, 
the mRNA level of the majority of the regulated genes coding for NC PTPs was increased during 
this process (Figure R2 and Table R2), suggesting that these PTPs might have a regulatory role 
in Th1 polarization or effector function.  
 
Th1 restimulation caused both gene up- and downregulation. This might indicate that once an 
effector cell is recruited to the site of inflammation, it needs to reorganize a wide range of 
intracellular signaling networks to respond adequately, and that these networks are, at least in 
part, regulated by PTPs. Taken together, changes in expression levels of genes coding for PTPs 
during both Th1 polarization and Th1 restimulation might uncover a role of these proteins in T 
cell responses. 
 
1.1 Regulators of cytokine signaling and secretion 
 
The classical PTPs PTPN9 (coding for PTP-MEG2) and PTPN13 (coding for PTP-BAS or PTP-BL), 
which in T cells regulate cytokine secretion and signaling, respectively, were significantly 
upregulated during Th1 polarization (Table R2).  
 
PTP-MEG2 regulates the fusion of secretory vesicles and promotes cytokine secretion by 
dephosphoorylating the N-ethylmaleimide-sensitive factor (NSF) (168). Consistently, it has  
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been shown that PTP-MEG2-deficient T cells show impaired IL-2 secretion (169). Hence, the 
upregulation of PTPN9 found during Th1 polarization might reflect the increased cytokine 
secretion needed for effector T cell function. PTPN9 shared cluster with the 
myotubularin MTMR2 (Figure R2), a regulator of endosomal trafficking and phosphoinositide 
phosphorylation (98, 188), which was also upregulated during Th1 polarization (Table R2). 
Interestingly, PTP-MEG2 is activated by interaction with phosphoinositides (189, 190). Hence, 
the segregation of both genes in the same cluster might indicate a functional connection 
between these proteins. Whether MTMR2 is required for proper Th1 polarization and cytokine 
secretion should also be investigated. 
 
PTP-BL has been shown to dephosphorylate and inhibit STAT4 and STAT6, and its deficiency 
results in enhanced Th1 and Th2 differentiation (171). Hence, PTPN13 might be induced during 
Th1 polarization as a regulatory mechanism to decrease STAT6 signaling in Th1 cells. 
Interestingly, PTPN13 was found in the same cluster as PTPN18. Both PTPs have been 
suggested to regulate (PTPN18) or associate with (PTPN13) the actin cytoskeleton in non-
immune cells (191, 192), and they also shared cluster with the DSP SSH3, another regulator of 
the actin cytoskeleton (193). This result sets out the question of whether PTP-BL is also 
regulating the cytoskeleton dynamics in T cells.  
 
1.2 MAPK regulators 
 
The expression of MAPK regulators (MKPs and atypical DSPs) was regulated in both Th1 
polarization and PI treatment (Figures R2 and R3, and Table R2). MKPs are characterized by 
sharing MAPK substrates. For example, ERK is dephosphorylated by 13 different MKPs. As 
mentioned in the introduction, the spatial distribution of dephosphorylated MAPKs is 
regulated by the binding of MKPs (92). For example, the nuclear ERK-specific MKPs DUSP2 
DUSP4 and DUSP5 have been described to dephosphorylate ERK in the nucleus and induce its 
nuclear accumulation in the dephosphorylated (kinase inactive) form (92, 194, 195). On the 
contrary, the cytoplasmic DUSP6 dephosphorylates and retains ERK in the cytoplasm (92). The 
subcellular localization of dephosphorylated ERK is of great importance, because it can have 
functions nondependent on its kinase activity (196). For example, it has been proposed that 
binding of kinase-inactive ERK to DUSP6 increases the activity of this phosphatase towards p38 
(197), and dephosphorylated ERK2 can also regulate gene expression and cell cycle progression 
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(198, 199). Interestingly, not only MKPs can regulate the subcellular localization of ERK. It has 
been shown that also the catalytically inactive atypical DSP STYX is a nuclear anchor for both 
phospho- and dephosphorylated ERK, and that it competes with DUSP4 for ERK binding (200). 
Thus, more than simply having a role in down-modulating the response of the module, PTPs 
that regulate MAPKs determine the subcellular localization and crosstalk of MAPKs. In this 
regard, changes in the protein dose, as may be achieved by regulating their expression levels, 
may enable MKPs to compete with other molecules for the binding of MAPKs. The comparison 
of the levels of MAPK regulators in naïve and restimulated Th1 cells (Figure D1A) could then 
give an idea of the differential spatial distribution of ERK in each situation (Figure D1B). In 
naïve T cells, the module of MAPK regulators was dominated by the nuclear DUSP1, which is 
not able to bind dephosphorylated ERK, the cytoplasmic DUSP16, which has not been reported 
to retain ERK, and the nuclear DUSP2, able to anchor dephosphorylated ERK in the nucleus. By 
contrast, the MAPK regulators with higher expression in restimulated Th1 cells were the 
nuclear DUSP2, DUSP4 and DUSP5, which bind dephosphorylated ERK, promoting its 
accumulation in the nucleus, and the cytoplasmic DUSP6, able to retain dephosphorylated ERK 
in the cytoplasm. These data suggest that while in naïve T cells rapid nuclear translocation and 
transient phosphorylation of ERK should dominate the response, in restimulated effector cells 
dephosphorylated ERK is accumulated both in the cytoplasm and the nucleus, where it could 
exert functions nonrelated to its phosphorylation state. 
 
Some MAPK regulators have been proposed to have a role in T cell responses. The most 
relevant findings in relation to our results will be discussed below.  
 
The expression of DUSP5 was upregulated during Th1 restimulation (Figure R3A). This nuclear 
MKP has been reported to regulate Th17/Treg cell balance in a mouse model of autoimmune 
arthritis (201), and to participate in MAPK regulation during IL-2 signaling (181). Our data 
further points to a role of DUSP5 in regulation of T cell stimulation, although determining the 
mechanism of such regulation will require further research.  
 
We found that DUSP7, the gene coding for MKP-X, was upregulated during Th1 polarization 
(Table R2). The role of this ERK-selective cytoplasmic phosphatase in T cell activation or 
differentiation has not been addressed. However, our group has recently found that DUSP7 
expression is reduced in CD4 T cells of patients with rheumatoid arthritis with respect to 
healthy donors (202). Interestingly, such downregulation was restricted to patients with 
positive rheumatoid factor and anti-citrullinated protein antibodies, suggesting that MKP-X 
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could be involved in T/B cooperation. Altogether, our findings point to a requirement of DUSP7 
for proper T cell effector function. 
 
The expression of DUSP22, coding for the atypical DSP VHX, was upregulated during Th1 
polarization (Table R2). VHX has been reported to control TCR signaling through different 
mechanisms. Initially, it was described as negative regulator of TCR-induced ERK2 activation 
(203), but recently it has also been shown to inactivate Lck (204). In addition, DUSP22 
knockout mice show exacerbated autoimmunity (204), and T cells of patients with nefritis 
associated to systemic lupus erythematosus (SLE) have less DUSP22 expression than SLE 
patients without nefritis (205). The upregulation during Th1 polarization found in our work 
suggests that it is involved in Th1 responses. Given the role of Th17 cells in development of 
autoimmunity, it would be interesting to study the expression and role of DUSP22 in Th17 
polarization.  
 
In this work, the expression of two MAPK regulators, DUSP8 and DUSP23, was significantly 
regulated during both Th1 polarization and restimulation.  
 
DUSP8 is a JNK/p38-selective MKP that has been identified as an upregulated gene in fungal 
infections (206), but its role in T cell responses has not been addressed. Interestingly, we found 
downregulation of DUSP8 during Th1 polarization (Figure R2) and upregulation during Th1 
restimulation (Figure R3A), suggesting that the requirements of this protein are different in N 
and effector Th1 cells.  
 
DUSP23 is able dephosphorylate ERK in vitro (207), but no studies in vivo are available. 
Recently, it has been proposed that DUSP23 dephosphorylates β-catenin in epithelial cells 
(208). β-catenin is recruited to the IS, where it could anchor dynein (38).  This finding, together 
with its location at the centrosome (209), suggests that DUSP23 could play a role in the 
assembly of the IS, and, consequently, in T cell activation. Our data showed a significant 
upregulation of DUSP23 during both Th1 polarization and restimulation (Figures R2 and R3A). 
Interestingly, overexpression of DUSP23 in CD4 T cells of patients with systemic lupus 
erythematosus has been described (210), further pointing to a role of this phosphatase in T cell 
responses. Hence, studying the distribution and substrates of DUSP23 in T cells would be of 
great interest. 
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Figure D1. Expression of MAPK regulators in naïve and restimulated Th1 cells. A. Agglomerative hierarchical tree 
of the expression profile of MAPK regulators naïve and restimulated Th1 (Th1-PI) cells. Numbers under the tree 
indicate the Euclidean distance among the expression profile. Hitmap represents the average DCT obtained for each 
gene in four donors. Calibration bar between 5 and 20 DCT is shown. B. Schematic representation of the proposed 
spatial regulation of ERK during CD4 T cell immune responses. Dominance of partners of the dephosphorylated ERK 
in cytoplasm or nucleus might mediate the accumulation of this MAPK and, consequently, promote ERK functions 
nonmediated by the kinase activity in restimulated Th1 cells. 
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1.3 Cell cycle regulators 
It should be noted that while naïve cells are quiescent, the effector cells generated in this work 
were proliferating at the moment of the analysis. Therefore, some of the genes found 
upregulated in Th1 cells could be promoters of cell cycle progression or mitosis. This is the case 
for CDC25A and CDC25B, which are known to cooperate to induce mitosis (211). Consistently, 
it has been shown that PD-1 inhibits T cell proliferation through suppression of CDC25A (212). 
Regarding CDC25B, recent findings suggest that it may play a role in T cell responses. Our 
group has recently found that CDC25B expression is impaired in CD4 T cells from patients with 
rheumatoid arthritis (RA) (202) , an autoimmune disease in which T cells play a central role 
(213). In the present work, we also found downregulation of CDC25B during restimulation of 
Th1 cells (Figure R3B), suggesting that the decreased levels of CDC25B found in RA patients 
could reflect the high inflammatory environment in RA pathology. Consistent with this idea, 
low levels of CDC25B correlated with the disease activity in RA patients (202). In addition, it 
has been reported that the CDC25B-specific kinase Aurora A participates in T cell activation 
sustaining signaling downstream the TCR (214). In this work, we found upregulation of CDC25B 
after Th1 polarization (Table R2). This result further suggests that CDC25B could have a 
function during T cell responses in addition to its role as a cell cycle regulator. 
 
1.4 Phosphoinositide phosphatases 
Among MTMs, two of them, MTMR2 and MTMR11 were significantly regulated during both 
Th1 polarization and Th1 restimulation (Figures 2 and 3C, and Table 2).  The role of MTMR2 in 
immune cells has not been addressed, but it has been reported that it interacts with Disc large-
1 (Dlg-1) (215), a protein that has been shown to regulate NFAT activation downstream the 
TCR through p38 (216). Recently, it has also been proposed that ezrin controls tubulin 
cytoskeleton dynamics, immunological synapse organization, and NFAT activation by 
interacting with Dlg-1 (217). Thus, it is conceivable that MTMR2 could also have a regulatory 
role in IS organization and Th1 cell activation through interaction with Dlg-1. In addition, it has 
been suggested that MTMR2 sustains Akt signaling by dephosphorylating PI(3,5)P2 to PI5P 
(218). Hence, MTMR2 could function as a promoter of the Akt/mTOR pathway activated during 
T cell stimulation. Our results show upregulation of MTMR2 during both Th1 polarization and 
Th1 restimulation, supporting a requirement of this enzyme in the response of Th1 cells. 
Unravel the role of MTMR2 in the context of T cell activation will need further research. 
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The PD MTMR11 was induced with Th1 polarization and upregulated during PI treatment. PD 
MTMs physically interact and increase the catalytic activity of active MTMs (188), playing a key 
role in the regulation of this group of phosphatases. The binding partners of MTMR11, 
however, remain unknown. Our results encourage further research on this MTM in T cells. 
 
1.5 SSHs 
Among the cofilin regulators SSHs, the expression of SSH1 did not change during Th1 
polarization or restimulation. This might indicate that the reported regulation of SSH1 activity 
through phosphorylation and interaction with other proteins (219) is enough to provide 
adequate levels of active SSH1 during Th1 responses. SSH2 expression was downregulated 
during both Th1 polarization and Th1 restimulation, while SSH3 expression was upregulated in 
the first process and downregulated in the second. The different regulation of SSHs expression 
in this study points to non-redundant functions of these phosphatases in T cells responses. This 
could be the case at least for SSH3, which dephosphorylates cofilin weaker than SSH1 and 2, 
and did not colocalize with F-actin when overexpressed in HeLa cells (59). Recent findings of 
our group suggest that at least SSH1 regulates actin dynamics at the IS (220), but further 
investigation will be required to determine the role of each SSH in T cell activation and Th 
polarization.   
 
 
2. Regulated expression of PRLs during T cell activation 
 
The group of PRLs showed no regulation during Th1 polarization (Figure R2). Currently there is 
no information on the role of these phosphatases in T cell activation or Th polarization. The 
only datum available comes from the screening of a mouse phosphatase shRNA library where 
PRL-3-knockdown Th1 cells did not lose Tbet expression upon Th2-polarizing conditions (177). 
Although the authors do not discuss it further, their data suggest that PRL-3 might have a role 
in Th2 commitment or Th1/Th2 plasticity. Our results do not point to a different requirement 
in the levels of PRL-3 between naive and Th1 cells in human, but whether this is also the case 
for Th2 cells will require further research.  
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Interestingly, each member of the PRL subfamily showed a distinct pattern of expression upon 
Th1 restimulation (Figure R3E). PTP4A1 was upregulated, PTP4A2 downregulated, and PTP4A3, 
the PRL with the lowest expression, did not significantly change. Time-course analysis of PRLs 
expression in more donors confirmed the initial results in Th1 cells, showing increased levels of 
PTP4A1 after 120 minutes of PI stimulation which were maintained until 240 minutes (Figure 
R4C). In peripheral blood CD4 T cells, however, the induction of PTP4A1 was more transient 
and smaller than in Th1 cells, and it was downmodulated from 120 minutes onwards (Figure 
R4B). Such differences between Th1 and peripheral blood CD4 T cells could be explained by the 
fact that peripheral blood CD4 T cells were in a resting state at the moment of PI treatment, 
while Th1 cells had been stimulated previously with anti-CD3ε and CD28 antibodies for several 
days and were actively proliferating before the experiment. A differential regulation of PTP4A1 
expression in proliferating versus quiescent cells could explain our results. Consistent with this 
idea, PRL-1 is upregulated in mitogen-stimulated cells (106) and participates in mitosis (114). 
Besides, PRL-1 induction could depend on the activation state of cells. In our results, Th1 cells 
induced higher levels of both the CD69 and PTP4A1 than CD4 T cells (Figure R4B, C and D), 
suggesting that higher activation induces higher PRL-1 function. This idea is further suggested 
by the positive correlation between PRL-1 and CD3ζ recruitment to the IS shown in Figure R7C. 
The upregulation of PTP4A1 expression during T cell stimulation could be driven by the 
transcription factor Egr-1 (early growth response 1), which has been shown to regulate PTP4A1 
expression (221) and is also induced within the first hour of T cell stimulation (222). 
 
The relative expression of PRLs was similar in peripheral blood CD4 and Th1 cells, with PTP4A2 
being the most abundant, followed by PTP4A1 and PTP4A3 (Figure R4A). However, the 
differential regulation of PTP4A1 and PTP4A2 during stimulation with PMA and Ionomycin 
changed this expression pattern, balancing PTP4A1 and PTP4A2 expression after 120 minutes 
of stimulation in both Th1 and CD4 T cells (Figure D2). Whether downregulation of PTP4A2 
levels is necessary for T cell function after stimulation remains to be determined. Here, we 
focused in the study of PRL-1 function, since expression data suggested that its function should 
prevail over PRL-2 function during T cell stimulation.   
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Figure D2. Regulation of the balance between PTP4A1 and PTP4A2 expression upon T cell stimulation. DCT of 
PTP4A1 and PTP4A2 in CD4 T cells before (left graph) and after (right graph) stimulation with PMA and Ionomycin. 
The higher levels of PTP4A2 before stimulation and the balanced expression of both genes after stimulation are 
represented by weighing scales.   
 
 
3. Recruitment of PRL-1 to the IS 
 
 
Taken together, our data show that PRL-1, which in unstimulated cells is located around the 
MTOC and at the plasma membrane, is polarized to the IS, suggesting a regulatory role of this 
protein in IS assembly or in signaling following antigenic stimulation (Figure D3). In our model, 
PRL-1 was delivered to the IS in two waves: an initial delivery to the plasma membrane 
contacting the APC, where PRL-1 could regulate actin dynamics, and a later delivery together 
with the MTOC where it showed localization at CD3ζ sites. PRL-1 was also present at the 
plasma membrane at the mature IS, where it also showed partial colocalization with LFA-I and 
surface CD3ε.  
 
Localization of PRL-1 at scanning membranes was fast and transient (Figure R10A, see white 
arrows, and Movie 1), suggesting that there is a pool of protein able to rapidly diffuse from the 
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cytosol to sites where actin polymerization must take place. The regulatory role of PRL-1 in 
actin dynamics and lamellipodium formation will be discussed further in the next section.   
The endosomal localization of PRL-1 reported in this work is consistent with previous 
observation of this protein at the early endosomal compartment in chinese hamster ovary 
(CHO) cells (115). The endosomal compartment is organized around the MTOC, from which 
microvesicles are directed to the IS through the microtubular network (223). This 
compartment plays an important role during every stage of T cell stimulation. Polarized 
recycling from the endosomal compartment has been proposed to be a mechanism for TCR 
accumulation at the IS (224), contributing to mature IS formation. Dynamic interaction 
between signaling complexes at the plasma membrane and intracellular vesicles carrying 
signaling molecules like LAT seems to contribute to the signaling process (225), and 
endocytosis of signaling complexes to the endosomal compartment has been suggested to 
mediate TCR signal extinction at the cSMAC (226, 227). Hence, localization of PRL-1 at the 
pericentriolar area suggests a role of the protein in controlling the microtubule dynamics, the 
endosomal traffic and potentially the IS organization. In fact, trafficking of the GTPase Rac-1, 
which is also localized at the pericentrosomal compartment, has been shown to regulate IS 
assembly and IL-2 secretion (228), and molecules involved in early signalling downstream the 
TCR, such as Lck and LAT, are also located at pericentrosomal vesicles (229). In the case of PRL-
1, the reported binding to tubulin in vitro and the localization to the mitotic spindle during 
mitosis (114) suggest that it could regulate endosomal dynamics through rearrangement of 
microtubules. In addition, presence of PRL-1 in vesicles containing CD3ζ (Figures R10B, R11A, 
R13B, and Movies 2 and 4) suggests that PRL-1 could be regulating TCR recruitment to the IS or 
sustained signaling for full T cell activation. Further characterization of the endosomes where 
PRL-1 is localized during IS formation would be useful to determine the role of PRL-1 in TCR 
recruitment to the IS or in sustaining signaling. Of note, recent data in epithelial cells show that 
PRL-3 enhances clathrin-mediated endocytosis through dephosphorylation of PI(4,5)P2, which 
might promote intracellular trafficking of transmembrane proteins (Mäja Kohn group, oral 
communication at the EMBO meeting "Europhosphatase 2017", Paris). Given the high identity 
between both proteins, it is conceivable that PRL-1 could also regulate endocytosis, and, 
therefore, play a role in traffic of TCR complexes during T cell stimulation.  
 
The presence of PRL-1 at the plasma membrane contacting the APC, where it partially 
colocalized with CD3ζ (Figure R10B) and CD3ε (Figure R12), and the positive correlation found 
between PRL-1 and CD3ζ polarization at the IS (Figure R7C) suggested that PRL-1 substrates are 
DISCUSSION 
 
103 
 
present in TCR signaling complexes, or that PRL-1 participates in TCR recruitment to the IS, or 
both.  As will be discussed in section 5 of this Discussion, in this work we provide evidences 
that PRL-1 regulates actin dynamics at the IS. Hence, PRL-1 might link signalling downstream 
the TCR and actin rearrangements during IS assembly through a mechanism that remains to be 
determined. 
 
 
  
Figure D3. Model for PRL-1 distribution of PRL-1 at the IS. The recruitment of PRL-1 to the IS in two waves is 
schematized 
 
 
The observed recruitment of PRL-1 to the IS and to vesicles containing CD3ζ was dependent on 
the presence of the CAAX motif (CCIQ in PRL-1), as shown by the overexpression of a mutant 
lacking this sequence (Figure R11B). Our finding is consistent with previous works which 
showed that either deletion of the whole CAAX motif, mutation of the first cysteine or 
treatment with farnesyltransferase inhibitors delocalized PRL-1 from plasma and 
endomembranes and localized it in the nucleus and the cytosol (112, 114-116). Since the 
mutant used in this work lacked the complete CAAX motif, we cannot determine if 
delocalization of the ΔCAAX mutant was due only to absence of farnesylation of the first Cys or 
if palmitoylation of the second Cys, as proposed for PRL-3 (117), was also involved. Our data 
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also point to the notion that in absence of farnesylation the polybasic region is not sufficient 
for membrane and endosomal targeting of PRL-1, but whether this region contributes to the 
enrichment of the farnesylated protein to the membrane and the IS has not been addressed in 
our work. Data from other groups has shown that in HEK293 cells the polybasic region is 
indeed necessary for proper localization of PRL-1 at the inner face of the plasma membrane 
(112). Hence, it would be interesting to study the distribution of a mutant lacking the polybasic 
region during IS formation. Besides, PRL-1 has been shown to form trimers and dimers in vivo, 
a condition that is proposed to stabilize PRL-1 at membranes and to be necessary to its cellular 
function (112, 120). In fact, inhibitors of PRL-1 trimerization have been shown to decrease PRL-
1-mediated cell proliferation and invasion (230).  It would be interesting to investigate the 
effect of the inhibition of PRL-1 oligomerization on PRL-1 delivery to the IS and on T cell 
activation.    
 
 
4. Contribution of PRL-1 to T cell activation 
 
 
In the present work, we show that specific inhibition of the catalytic activity of PRLs with TP 
results in decreased CD69 induction and IL-2 secretion upon T cell stimulation (Figure R5), 
indicating that PRLs are active enzymes in vivo and that their catalytic activity is required for 
full T cell activation. This is consistent with previous works showing that the oncogenic 
activities of PRLs require their catalytic activity (116, 147, 231). The use of the PRL-1-specific 
inhibitor PB3 revealed that PRL-1 phosphatase activity contributes to IL-2 secretion during T 
cell stimulation (Figure R15B, right panel). The effect of PRL-1 inhibition was, however, smaller 
than the effect of inhibiting the three PRLs, suggesting that these proteins might have 
overlapping functions in regulation of T cell activation. This is conceivable, given the high 
identity between PRLs (95), and given that PRL-1, PRL-2 and PRL-3 show similar subcellular 
distribution in J77 cells and the three of them are recruited to the IS (data not shown). 
Remarkably, PRL-1 inhibition decreased CD69 induction only slightly, not reaching statistical 
significance (Figure R14B, left panel). Hence, our data might indicate that PRL-2 and PRL-3 
catalytic activity would also participate in T cell activation, being the main contributors to CD69 
induction. It would be interesting to study the function of each member of the PRL family 
during T cell stimulation, in order to determine whether they have or not overlapping 
functions in T cell signalling. Regarding PRL-2, it has recently been shown that it is involved in T 
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cell development (146), but whether it also regulates mature T cell responses has not been 
addressed. Regarding PRL-3, the proposed substrates ezrin (125) and PI(4,5)P2 (126) in non-
immune cell types strongly encourages further research in T cells. 
 
PRL-1 overexpression led to a clear increase in CD69 surface expression upon T cell 
stimulation, while inhibition of PRL-1 catalytic activity decreased CD69 induction only weakly 
(Figure R14). Such discrepancy could be explained by the fact that when PRL-1 is 
overexpressed, both phosphatase dependent and independent activities are enhanced, while 
when using an inhibitor, phosphatase activity is decreased, but functions independent on 
dephosphorylation remain intact. Hence, increased CD69 induction observed when 
overexpressing PRL-1 could be mediated, at least in part, by a mechanism independent of PRL-
1 catalytic activity. To address this issue, it would be useful to study the effect of interfering 
PRL-1 expression, or the effect of overexpressing a catalytically inactive mutant. Of note, it has 
been proposed that PRL-1 promotes ERK-1/2 activation by binding and displacing the MEKK1 
inhibitor p115RhoGAP (141). Binding to p115RhoGAP does not take place through the catalytic 
region of PRL-1, but whether this mechanism indirectly requires phosphatase activity remains 
to be determined. Although p115RhoGAP is expressed by T cells (232), we have not detected 
enhanced ERK-1/2 phosphorylation when overexpressing or inhibiting PRL-1 (Figure R16B). 
Hence, an alternative mechanism should be behind PRL-1-mediated upregulation of CD69. 
Such mechanism could be mediated by the actin rearrangements and PLCγ1 activation, as will 
be discussed in the next section. It is also conceivable that PRL-1 regulates T cell signalling by a 
mechanism involving its catalytic activity, but independent on actin dynamics. Until date, the 
only substrate proposed for PRL-1 is ATF-7 (124). This activating transcription factor belongs to 
the AP-1 family (233). Hence, it might be involved in regulation of IL-2 expression during T cell 
activation. In fact, the related ATF-2 has been shown to induce IFNγ expression in T cells (234). 
It would be interesting to determine if the enhanced IL-2 secretion we found is a result of 
enhanced gene expression or increased exocytosis. Besides, our work suggests the existence of 
yet unknown substrates of PRL-1 at the IS, specially at sites enriched in CD3 and LFA-I, and at 
the pericentriolar compartment. Further research will be needed to identify such substrates. 
 
 
 
 
DISCUSSION 
 
 
106 
 
5. PRL-1 regulates actin dynamics at the IS 
 
 
In this work, we show that PRL-1 is rapidly recruited to membrane protrusions during the 
scanning phase of IS formation (Figure R10A and Movie 1) and to sites of actin polymerization 
during early contact with activating surfaces (Figure R14A and Movie 6). These observations 
suggested that PRL-1 was regulating actin dynamics during initial steps of IS formation.  
 
Initial scanning of the APC by the moving T cell leads to TCR and LFA-I engagement at the 
leading lamellipodium. TCR and LFA-I engagement induces a stable contact between the APC 
and the T cell (9). Actin polymerizes at the leading edge of moving cells, and the formation of 
the lamellipodium is regulated by the actin nucleation factor Wave2, as demonstrated by the 
fact that knockdown of Wave2 in Jurkat T cells impairs cell spreading on anti-CD3 coated 
coverslips (52). Interestingly, we observed that PRL-1 overexpression in J77 cells also led to 
impaired cell spreading on activating surfaces (Figure R15B), showing a similar, although less 
dramatic effect than Wave2 knockdown.  This result suggested that PRL-1 could be inhibiting 
Wave2 function. Wave2 is activated by the Rho family GTPase Rac1 (235), which is transiently 
activated upon TCR and LFA-I stimulation  (48, 236). Interestingly, two different groups have 
shown that overexpression of PRL-1 in epithelial cells leads to decreased GTP-Rac (active) 
levels, without altering total Rac (116, 147). This effect seems to be independent on the 
phosphatase activity, since overexpression of catalytically inactive mutants of PRL-1 also 
decrease Rac activation (147). Hence, the impaired cell spreading reported in our work could 
be due to a defective Wave2 activation, caused by PRL-1-mediated inhibition of Rac1. It would 
be interesting to analyze GTP-Rac1 levels in T cells overexpressing PRL-1 to determine if this 
regulatory pathway is indeed taking place in our system, and to confirm if this effect is 
independent of PRL-1 catalytic activity, as previously reported (147).  
 
During cell spreading, actin is polymerized at the periphery of the interaction and 
depolymerized at the central area, leading to the formation of a dynamic actin ring (186). As 
mentioned in the introduction, actin depolymerization at the IS is promoted by cofilin, an actin 
severing protein that is activated during TCR/CD28 signaling (58) and inactivated downstream 
RhoA/ROCK/LIMK pathway (61, 62). In this work, we observed that PRL-1 overexpression 
impaired actin clearance during IS assembly (Figure R15B), suggesting that actin 
depolymerization could be regulated by PRL-1. Interestingly, PRL-1 has been shown to activate 
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RhoA in a manner that requires its catalytic activity (116, 147). Hence, overexpression of PRL-1 
in J77 cells might enhance RhoA activation, leading to an increase in LIMK activity that would 
result in augmented cofilin inhibition and, as a consequence, defective actin depolymerization 
at the IS (Figure D4A).  
 
In the present work, we also observed that inhibition of the catalytic activity of PRL-1 resulted 
in decreased F-actin accumulation at the IS (Figure R15C).  This phenotype could be due to 
increased actin depolymerization. As mentioned before, actin depolymerization is induced by 
the RhoA/ROCK/LIMK pathway (61, 62), and PRL-1 has been shown to activate RhoA by a 
mechanism that requires its catalytic activity (116, 147). Although the cited works were 
performed overexpressing WT or catalyticallt inactive mutants of PRL-1, it is conceivable that 
endogenous PRL-1 might also be maintaining basal levels of active RhoA through its enzymatic 
activity. Hence, inhibition of PRL-1 catalytic activity would result in impaired RhoA activation, 
leading to accumulation of active cofilin and, a consequence, enhanced actin depolymerization 
and less F-actin at the IS (Figure D4B). Interestingly, crosstalk between RhoA and signaling 
through LFA-I has been reported. It has been proposed that RhoA is activated by the 
cytoplasmic protein cytohesin-1 (237), which binds to and activates LFA-I in Jurkat cells (238). 
Besides, it has been shown that in lymphocytes RhoA enhances LFA-I adhesion to ICAM-I by 
inducing LFA-I high affinity state (239). The high colocalization found between GFP-PRL-1 and 
LFA-I at the mature IS in this work (Figure R12) suggests that PRL-1 could be involved in the 
crosstalk between LFA-I and RhoA, linking integrin signaling and regulation of actin dynamics at 
the IS. 
 
Proper actin flow is required for sustaining T cell signalling, including PLCγ1 activation (15). In 
this work, we found decreased PLCγ1 activation when PRL-1 was inhibited, and enhanced 
PLCγ1 phosphorylation when PRL-1 was overexpressed (Figure R16A). Hence, in our system, 
defective actin phosphorylation upon PRL-1 activation could result in defective formation of 
signaling clusters, leading to decreased PLCγ1 activation and, as a consequence, less IL-2 
secretion and CD69 expression. By contrast, increased actin polymerization at the area of 
contact induced by PRL-1 overexpression could maintain signaling clusters at the interaction 
for longer times, sustaining early signaling. This would lead to enhanced PLCγ1 activation, and 
consequently to increased IL-2 secretion and CD69 induction.   
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Figure D4. Regulation of actin dynamics by PRL-1 through activation of RhoA. A. Effect of  PRL-1 overexpression in 
regulation of actin dynamics. GFP-PRL-1 is represented as a green hexagon, and endogenous PRL-1 as a light green 
ellipse. B. Effect of endogenous PRL-1 inhibition by PB3. Grey arrows indicate activation. Red line indicates 
inhibition. Orange arrows indicate dynamics of actin.   
 
Altogether, our data point to a role of PRL-1 in regulating actin polymerization during IS 
assembly, and consequently T cell signaling required for full T cell activation. This is consistent 
with previous findings in cancer models, and provides the first evidence of a role of PRL-1 in 
cytoskeletal rearrangements and T cell activation 
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CONCLUSIONS 
 
1. Th1 polarization induces upregulation of the expression levels of several NC PTPs, 
suggesting a different requirement of these enzimes in naïve versus effector cells. 
 
2. The expression of several NC PTPs is regulated upon stimulation of Th1 cells, 
suggesting that some of these enzimes could be novel regulators of T cell effector 
function in responses at sites of inflammation.   
 
3. PRLs might regulate T cell activation, as suggested by the fact that (i) their expression 
levels in CD4 T cells are comparable to that of PTPs known to regulate T cell activation, 
(ii) the expression of PTP4A1 and PTP4A2 is regulated during T cell activation, resulting 
in a balanced expression of both genes, and (iii) the catalytic activity of PRLs is required 
for T cell activation 
 
4. PRL-1 participates in IS assembly and signaling, as suggested by its recruitment to the 
IS in two waves: an initial recruitment to scanning membranes and a later delivery in 
the endosomal compartment at the stablished IS, where it colocalizes with LFA-I and 
CD3 
 
5. PRL-1 regulates actin rearrangements during IS assembly and positively regulates PLCγ-
1 activation and IL-2 secretion during T cell stimulation through a mechanism involving 
its catalytic activity. 
 
 
Altogether, our data encourage further research on the role of NC PTPs in T cell responses and 
provides evidences that PRL-1 is a positive regulator of T cell stimulation 
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